Advertisement

Uroonkologie pp 485-635 | Cite as

Prostatakarzinom

  • Christof Börgermann
  • Felix K. -H. Chun
  • Paolo Fornara
  • Michael Fröhner
  • Markus Graefen
  • Alexander Haese
  • Peter Hammerer
  • Karsten Heine
  • Hartwig Huland
  • J. Köllermann
  • Hagen Loertzer
  • Hans-Joachim Luboldt
  • Kurt Miller
  • Herbert Rübben
  • Thorsten Schlomm
  • Martin Schostak
  • Mark Schrader
  • Rudolf Schwarz
  • Axel Semjonow
  • Sigried Wagner
  • Manfred Wirth
  • Johannes M. Wolff

Zusammenfassung

Über die vergangenen Jahrzehnte hat sich das Prostatakarzinom (PCA), trotz auffälliger Diskrepanz in der Inzidenz, über ethnische Grenzen hinweg weltweit zu einem der dominierenden Malignome des Mannes entwickelt. Sowohl in den Hoch- wie auch in Niedrigrisikopopulationen der Welt stieg bzw. steigt die Inzidenz deutlich an, eine Tendenz, die sich durch die zunehmende Lebenserwartung noch fortsetzen dürfte [1].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu Kap. 25.1

  1. 1.
    Hsing AW, Devesa SS (2001) Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 23: 3–13PubMedGoogle Scholar
  2. 2.
    Franks LM (1954) Latent carcinoma of the prostate. J Pathol Bacteriol 68: 603–616PubMedCrossRefGoogle Scholar
  3. 3.
    Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ et al. (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo 8: 439–443PubMedGoogle Scholar
  4. 4.
    Society AC (2003) Cancer facts and figures 2003, Atlanta, GA. 2003Google Scholar
  5. 6.
    Sim HG, Cheng CW (2005) Changing demography of prostate cancer in Asia. Eur J Cancer 41:834–845.PubMedCrossRefGoogle Scholar
  6. 7.
    Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. Jama 273: 548–552PubMedCrossRefGoogle Scholar
  7. 8.
    Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC et al. (1999) Cancer surveillance series: interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91: 1017–1024PubMedCrossRefGoogle Scholar
  8. 9.
    Osegbe DN (1997) Prostate cancer in Nigerians: facts and nonfacts. J Urol 157: 1340–1343PubMedCrossRefGoogle Scholar
  9. 10.
    Potosky AL, Kessler L, Gridley G, Brown CC, Horm JW (1990) Rise in prostatic cancer incidence associated with increased use of transurethral resection. J Natl Cancer Inst 82: 1624–1628PubMedCrossRefGoogle Scholar
  10. 11.
    Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L et al. (2004) SEER Cancer Statistics Review 1975–2001, 2004Google Scholar
  11. 12.
    Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL (1996) The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence — data from the Utah Cancer Registry. Cancer 77: 1342–1348PubMedCrossRefGoogle Scholar
  12. 13.
    Baade PD, Coory MD, Aitken JF (2004) International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control 15: 237–241PubMedCrossRefGoogle Scholar
  13. 14.
    Morganti G, Gianferrari L, Cresseri A, Arrigoni G, Lovati G (1956) Clinico-statistical and genetic research on neoplasms of the prostate. Acta Genet Stat Med 6: 304–305PubMedGoogle Scholar
  14. 15.
    Stanford JL, Ostrander EA (2001) Familial prostate cancer. Epidemiol Rev 23: 19–23PubMedGoogle Scholar
  15. 16.
    Carter BS, Boya GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB et al. (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150: 797–802PubMedGoogle Scholar
  16. 17.
    Zeegers MP, Jellema A, Ostrer H (2003) Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 97: 1894–1903PubMedCrossRefGoogle Scholar
  17. 18.
    Siesling S, van Dijck JA, Visser O, Coebergh JW (2003) Trends in incidence of and mortality from cancer in The Netherlands in the period 1989–1998. Eur J Cancer 39: 2521–2530PubMedCrossRefGoogle Scholar
  18. 19.
    Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. (2004) Cancer statistics 2004. CA Cancer J Clin 54: 8–29PubMedCrossRefGoogle Scholar
  19. 20.
    Glover FE, Jr., Coffey DS, Douglas LL, Russell H, Cadigan M, Tulloch T et al. (1998) Familial study of prostate cancer in Jamaica. Urology 52: 441–443PubMedCrossRefGoogle Scholar
  20. 21.
    Glover FE, Jr., Coffey DS, Douglas LL, Cadogan M, Russell H, Tulloch T et al. (1998) The epidemiology of prostate cancer in Jamaica. J Urol 159: 1984–1986; discussion 1986–1987PubMedCrossRefGoogle Scholar
  21. 22.
    Powell IJ, Banerjee M, Novallo M, Sakr W, Grignon D, Wood DP et al. (2000) Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease. Urology 55: 246–251PubMedCrossRefGoogle Scholar
  22. 23.
    Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL et al. (2001) Racial and ethnic differences in advancedstage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93: 388–395PubMedCrossRefGoogle Scholar
  23. 24.
    Merrill RM, Lyon JL (2000) Explaining the difference in prostate cancer mortality rates between white and black men in the United States. Urology 55: 730–735PubMedCrossRefGoogle Scholar
  24. 25.
    Haenszel W, Kurihara M (1968) Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40: 43–68PubMedGoogle Scholar
  25. 26.
    Yu H, Harris RE, Gao YT, Gao R, Wynder EL (1991) Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States. Int J Epidemiol 20: 76–81PubMedCrossRefGoogle Scholar
  26. 27.
    Kritchevsky D (1999) Caloric restriction and experimental carcinogenesis. Toxicol Sci 52: 13–16PubMedGoogle Scholar
  27. 28.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625–1638PubMedCrossRefGoogle Scholar
  28. 29.
    Thompson HJ, Jiang W, Zhu Z (1999) Mechanisms by which energy restriction inhibits carcinogenesis. Adv Exp Med Biol 470: 77–84PubMedGoogle Scholar
  29. 30.
    Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK (1999) Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 91: 512–523PubMedCrossRefGoogle Scholar
  30. 31.
    Platz EA (2002) Energy imbalance and prostate cancer. J Nutr 132: 3471S–3481SPubMedGoogle Scholar
  31. 32.
    Hsing AW (2001) Hormones and prostate cancer: what’s next? Epidemiol Rev 23: 42–58PubMedGoogle Scholar
  32. 33.
    Hsing AW, Chua S, Jr., Gao YT, Gentzschein E, Chang L, Deng J et al. (2001) Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 93: 783–789PubMedCrossRefGoogle Scholar
  33. 34.
    Chang S, Hursting SD, Contois JH, Strom SS, Yamamura Y, Babaian RJ et al. (2001) Leptin and prostate cancer. Prostate 46: 62–67PubMedCrossRefGoogle Scholar
  34. 35.
    Stattin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman UH et al. (2001) Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab 86: 1341–1345PubMedCrossRefGoogle Scholar
  35. 36.
    Platz EA, Leitzmann MF, Michaud DS, Willett WC, Giovannucci E (2003) Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res 63: 8542–8548PubMedGoogle Scholar
  36. 37.
    Nomura AM (2001) Body size and prostate cancer. Epidemiol Rev 23: 126–131PubMedGoogle Scholar
  37. 38.
    Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A et al. (1997) Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 89: 385–389PubMedCrossRefGoogle Scholar
  38. 39.
    Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA (2000) Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol 151: 541–549PubMedGoogle Scholar
  39. 40.
    Spitz MR, Strom SS, Yamamura Y, Troncoso P, Babaian RJ, Scardino PT et al. (2000) Epidemiologic determinants of clinically relevant prostate cancer. Int J Cancer 89: 259–264PubMedCrossRefGoogle Scholar
  40. 41.
    Rohrmann S, Roberts WW, Walsh PC, Platz EA (2003) Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer. Prostate 55: 140–146PubMedCrossRefGoogle Scholar
  41. 42.
    Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ (2001) Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10: 345–353PubMedGoogle Scholar
  42. 43.
    Freedland SJ, Platz EA, Presti JC, Jr., Aronson WJ, Amling CL, Kane CJ et al. (2006) Obesity, serum prostate spectific antigen and prostate size: implications for prostate cancer detection. J Urol 175: 500–504; discussion 504.PubMedCrossRefGoogle Scholar
  43. 44.
    Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J et al. (2005) The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103: 1092–1095PubMedCrossRefGoogle Scholar
  44. 45.
    Armstrong B, Doll R (1975) Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15: 617–631PubMedCrossRefGoogle Scholar
  45. 46.
    Rose DP, Boyar AP, Wynder EL (1986) International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer 58: 2363–2371PubMedCrossRefGoogle Scholar
  46. 47.
    Kushi L, Giovannucci E (2002) Dietary fat and cancer. Am J Med 113 Suppl 9B: 63S–70S.PubMedCrossRefGoogle Scholar
  47. 48.
    Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR et al. (1995) Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87: 652–661PubMedCrossRefGoogle Scholar
  48. 49.
    Hayes RB, Ziegler RG, Gridley G, Swanson C, Greenberg RS, Swanson GM et al. (1999) Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 8: 25–34PubMedGoogle Scholar
  49. 50.
    Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC et al. (1993) A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85: 1571–1579PubMedCrossRefGoogle Scholar
  50. 51.
    Andersson SO, Wolk A, Bergstrom R, Giovannucci E, Lindgren C, Baron J et al. (1996) Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. Int J Cancer 68: 716–722PubMedCrossRefGoogle Scholar
  51. 52.
    Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT (1997) A case-control study of diet and prostate cancer. Br J Cancer 76: 678–687PubMedGoogle Scholar
  52. 53.
    Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, Stampfer MJ (1994) Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 86: 281–286PubMedCrossRefGoogle Scholar
  53. 54.
    Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE, Vatten L (1997) Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer 71: 545–551PubMedCrossRefGoogle Scholar
  54. 55.
    Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM (2000) Men who consume vegetable oils rich in monounsaturated fat: their dietary patterns and risk of prostate cancer (New Zealand). Cancer Causes Control 11: 609–615PubMedCrossRefGoogle Scholar
  55. 56.
    Godley PA, Campbell MK, Gallagher P, Martinson FE, Mohler JL, Sandler RS (1996) Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol Biomarkers Prev 5: 889–895PubMedGoogle Scholar
  56. 57.
    Schuurman AG, van den Brandt PA, Dorant E, Brants HA, Goldbohm RA (1999) Association of energy and fat intake with prostate carcinoma risk: results from The Netherlands Cohort Study. Cancer 86: 1019–1027PubMedCrossRefGoogle Scholar
  57. 58.
    Veierod MB, Laake P, Thelle DS: Dietary fat intake and risk of prostate cancer (1997) a prospective study of 25.708 Norwegian men. Int J Cancer 73: 634–638Google Scholar
  58. 59.
    Le Marchand L, Kolonel LN, Wilkens LR, Myers BC, Hirohata T (1994) Animal fat consumption and prostate cancer: a prospective study in Hawaii. Epidemiology 5: 276–282PubMedCrossRefGoogle Scholar
  59. 60.
    Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willet WC, Giovannucci E (2001) A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 12: 557–567PubMedCrossRefGoogle Scholar
  60. 61.
    Mills PK, Beeson WL, Phillips RL, Fraser GE (1989) Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64: 598–604PubMedCrossRefGoogle Scholar
  61. 62.
    Hsing AW, McLaughlin JK, Schuman LM, Bjelke E, Gridley G, Wacholder S et al. (1990) Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res 50: 6836–6840PubMedGoogle Scholar
  62. 63.
    Schuurman AG, van den Brandt PA, Dorant E, Goldbohm RA (1999) Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study. Br J Cancer 80: 1107–1113PubMedCrossRefGoogle Scholar
  63. 64.
    Nagao M. A new approach to risk estimation of food-borne carcinogens-heterocyclic amines-based on molecular information. Mutat Res 431: 3–12Google Scholar
  64. 65.
    Norrish AE, Ferguson LR, Knize MG, Felton JS, Sharpe SJ, Jackson RT (1999) Heterocyclic amine content of cooked meat and risk of prostate cancer. J Natl Cancer Inst 91: 2038–2044PubMedCrossRefGoogle Scholar
  65. 66.
    Grant WB (1999) An ecologic study of dietary links to prostate cancer. Altern Med Rev 4: 162–169PubMedGoogle Scholar
  66. 67.
    Talamini R, La Vecchia C, Decarli A, Negri E, Franceschi S (1986) Nutrition, social factors and prostatic cancer in a Northern Italian population. Br J Cancer 53: 817–821PubMedGoogle Scholar
  67. 68.
    Mettlin C, Selenskas S, Natarajan N, Huben R (1989) Beta-carotene and animal fats and their relationship to prostate cancer risk. A case-control study. Cancer 64: 605–612PubMedCrossRefGoogle Scholar
  68. 69.
    La Vecchia C, Negri E, D’Avanzo B, Franceschi S, Boyle P (1991) Dairy products and the risk of prostatic cancer. Oncology 48: 406–410PubMedCrossRefGoogle Scholar
  69. 70.
    Talamini R, Franceschi S, La Vecchia C, Serraino D, Barra S, Negri E (1992) Diet and prostatic cancer: a case-control study in northern Italy. Nutr Cancer 18: 277–286PubMedCrossRefGoogle Scholar
  70. 71.
    De Stefani E, Fierro L, Barrios E, Ronco A (1995) Tobacco, alchohol, diet and risk of prostate cancer. Tumori 81: 315–320PubMedGoogle Scholar
  71. 72.
    Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL (2001) Dairy products, calcium, and prostate cancer risk in the Physicians’ Health Study. Am J Clin Nutr 74: 549–554PubMedGoogle Scholar
  72. 73.
    Qin LQ, Xu JY, Wang PY, Kaneko T, Hoshi K, Sato A (2004) Milk consumption is a risk factor for prostate cancer: meta-analysis of case-control studies. Nutr Cancer 48: 22–27PubMedCrossRefGoogle Scholar
  73. 74.
    Kristal AR, Cohen JH, Qu P, Stanford JL (2002) Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 11: 719–725PubMedGoogle Scholar
  74. 75.
    Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A (1998) Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 9: 559–566PubMedCrossRefGoogle Scholar
  75. 76.
    Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA et al. (1998) Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58: 442–447PubMedGoogle Scholar
  76. 77.
    Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Fakhrabadi-Shokoohi D, Giovannucci EL et al. (2003) Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev 12: 597–603PubMedGoogle Scholar
  77. 78.
    Berndt SI, Carter HB, Landis PK, Tucker KL, Hsieh LJ, Metter EJ et al. (2002) Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology 60: 1118–1123PubMedCrossRefGoogle Scholar
  78. 79.
    Tavani A, Gallus S, Franceschi S, La Vecchia C (2001) Calcium, dairy products, and the risk of prostate cancer. Prostate 48: 118–121PubMedCrossRefGoogle Scholar
  79. 80.
    Sies H, Stahl W (1995) Vitamins E and C, beta-carotene, and other carotenoids and antioxidants. Am J Clin Nutr 62: 1315S–1321SPubMedGoogle Scholar
  80. 81.
    Kaplan LA, Stein EA, Willett WC, Stampfer MJ, Strykers WS (1987) Reference ranges of retinol, tocopherols, lycopene and alpha-and beta-carotene in plasma by simultaneous high-performance liquid chromatographic analysis. Clin Physiol Biochem 5: 297–304PubMedGoogle Scholar
  81. 82.
    Clinton SK, Emenhiser C, Schwartz SJ, Bostwick DG, Williams AW, Moore BJ et al. (1996) cis-trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev 5: 823–833PubMedGoogle Scholar
  82. 83.
    Stahl W, Sies H (1992) Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans. J Nutr 122: 2161–2166PubMedGoogle Scholar
  83. 84.
    Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC (2002) A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94: 391–398PubMedGoogle Scholar
  84. 85.
    Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH et al. (1999) Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 59: 1225–1230PubMedGoogle Scholar
  85. 86.
    Lu QY, Hung JC, Heber D, Go VL, Reuter VE, Cordon-Cardo C et al. (2001) Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol Biomarkers Prev 10: 749–756PubMedGoogle Scholar
  86. 87.
    Vogt TM, Mayne ST, Graubard BI, Swanson CA, Sowell AL, Schoenberg JB et al. (2002) Serum lycopene, other serum carotenoids, and risk of prostate cancer in US Blacks and Whites. Am J Epidemiol 155: 1023–1032PubMedCrossRefGoogle Scholar
  87. 88.
    Huang HY, Alberg AJ, Norkus EP, Hoffman SC, Comstock GW, Helzlsouer KJ (2003) Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol 157: 335–344PubMedCrossRefGoogle Scholar
  88. 89.
    Nomura AM, Stemmermann GN, Lee J, Craft NE (1997) Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. Cancer Epidemiol Biomarkers Prev 6: 487–491PubMedGoogle Scholar
  89. 90.
    Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA (1998) Vegetable and fruit consumption and prostate cancer risk: a cohort study in The Netherlands. Cancer Epidemiol Biomarkers Prev 7: 673–680PubMedGoogle Scholar
  90. 91.
    Cohen JH, Kristal AR, Stanford JL (2000) Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 92: 61–68PubMedCrossRefGoogle Scholar
  91. 92.
    Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR et al. (2000) Vegetables fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 9: 795–804PubMedGoogle Scholar
  92. 93.
    Kristal AR, Lampe JW (2002) Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer 42: 1–9PubMedCrossRefGoogle Scholar
  93. 94.
    Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC (2003) A prospective study of cruciferous vetetables and prostate cancer. Cancer Epidemiol Biomarkers Prev 12: 1403–1409PubMedGoogle Scholar
  94. 95.
    Morrissey C, Watson RW (2003) Phytoestrogens and prostate cancer. Curr Drug Targets 4: 231–241PubMedCrossRefGoogle Scholar
  95. 96.
    Severson RK, Nomura AM, Grove JS, Stemmermann GN (1989) A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 49: 1857–1860PubMedGoogle Scholar
  96. 97.
    The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330: 1029–1035Google Scholar
  97. 98.
    Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM et al. (1998) Prostate cancer and Supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90: 440–446PubMedCrossRefGoogle Scholar
  98. 99.
    Virtamo J, Pietinen P, Huttunen JK, Korhonen P, Malila N, Virtanen MJ et al. (2003) Incidence of cancer and mortality following alphatocopherol and beta-carotene Supplementation: a postintervention follow-up. Jama 290: 476–485PubMedCrossRefGoogle Scholar
  99. 100.
    Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL (1999) Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 8: 893–899PubMedGoogle Scholar
  100. 101.
    Eichholzer M, Stahelin HB, Gey KF, Ludin E, Bernasconi F (19) Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 66: 145–150CrossRefGoogle Scholar
  101. 102.
    Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM et al. (2005) Effects of long-term vitamin E Supplementation on cardiovascular events and cancer: a randomized controlled trial. Jama 293: 1338–1347PubMedCrossRefGoogle Scholar
  102. 103.
    Sporn MB, Roberts AB (1984) Role of retinoids in differentiation and carcinogenesis. J Natl Cancer Inst 73: 1381–1387PubMedGoogle Scholar
  103. 104.
    Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC: Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87: 1767–1776Google Scholar
  104. 105.
    Daviglus ML, Dyer AR, Persky V, Chavez N, Drum M, Goldberg J et al. (1996) Dietary beta-carotene, vitamin C, and risk of prostate cancer: results from the Western Electric Study. Epidemiology 7: 472–477PubMedCrossRefGoogle Scholar
  105. 106.
    Hsing AW, Comstock GW, Abbey H, Polk BF (1990) Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. J Natl Cancer Inst 82: 941–946PubMedCrossRefGoogle Scholar
  106. 107.
    Jain MG, Hislop GT, Howe GR, Ghadirian P (1999) Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. Nutr Cancer 34: 173–184PubMedCrossRefGoogle Scholar
  107. 108.
    Oishi K, Okada K, Yoshida O, Yamabe H, Ohno Y, Hayes RB et al. (1988) A case-control study of prostatic cancer with reference to dietary habits. Prostate 12: 179–190PubMedCrossRefGoogle Scholar
  108. 109.
    Menon M, Maramag C, Malhotra RK, Seethalakshmi L (1998) Effect of vitamin C on androgen independent prostate cancer cells (PC3 and Mat-Ly-Lu) in vitro: involvement of reactive oxygen species-effect on cell number, viability and DNA synthesis. Cancer Biochem Biophys 16: 17–30PubMedGoogle Scholar
  109. 110.
    Maramag C, Menon M, Balaji KC, Reddy PG, Laxmanan S (1997) Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability, and DNA synthesis. Prostate 32: 188–195PubMedCrossRefGoogle Scholar
  110. 111.
    Jamison JM, Gilloteaux J, Venugopal M, Koch JA, Sowick C, Shah R et al. (1996) Flow cytometric and ultrastructural aspects of the synergistic antitumor activity of vitamin C-vitamin K3 combinations against human prostatic carcinoma cells. Tissue Cell 28: 687–701PubMedCrossRefGoogle Scholar
  111. 112.
    Chan JM, Giovannucci EL (2001) Vegetables, fruits, associated micronutrients, and risk of prostate cancer. Epidemiol Rev 23: 82–86PubMedGoogle Scholar
  112. 113.
    Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL et al. (1999) Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev 8: 241–248PubMedGoogle Scholar
  113. 114.
    Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11: 847–852PubMedCrossRefGoogle Scholar
  114. 115.
    Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G et al. (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108: 104–108PubMedCrossRefGoogle Scholar
  115. 116.
    Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT et al. (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2: 467–472PubMedGoogle Scholar
  116. 117.
    Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW (1995) Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6: 235–239PubMedCrossRefGoogle Scholar
  117. 118.
    Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ (1996) Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5: 121–126PubMedGoogle Scholar
  118. 119.
    Luscombe CJ, Fryer AA, French ME, Liu S, Saxby MF, Jones PW et al. (2001) Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 358: 641–642PubMedCrossRefGoogle Scholar
  119. 120.
    Chan JM, Pietinen P, Virtanen M, Malila N, Tangrea J, Albanes D et al. (2000) Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control 11: 859–867PubMedCrossRefGoogle Scholar
  120. 121.
    Clark LC, Combs GF, Jr., Turnbull BW, Slate EH, Chalker DK, Chow J et al. (1996) Effects of selenium Supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial Nutritional Prevention of Cancer Study Group. Jama 276: 1957–1963PubMedCrossRefGoogle Scholar
  121. 122.
    Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP et al. (2000) Association between alpha-tocopherol, gammatocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 92: 2018–2023PubMedCrossRefGoogle Scholar
  122. 123.
    Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB et al. (1998) Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90: 1219–1224PubMedCrossRefGoogle Scholar
  123. 124.
    Vogt TM, Ziegler RG, Graubard BI, Swanson CA, Greenberg RS, Schoenberg JB et al. (2003) Serum selenium and risk of prostate cancer in U.S. blacks and whites. Int J Cancer 103: 664–670PubMedCrossRefGoogle Scholar
  124. 125.
    Nomura AM, Lee J, Stemmermann GN, Combs GF, Jr. (2000) Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 9: 883–887PubMedGoogle Scholar
  125. 126.
    Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG et al. (2001) Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166: 2034–2038PubMedCrossRefGoogle Scholar
  126. 127.
    Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, Gaziano JM et al. (2004) A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 96: 696–703PubMedGoogle Scholar
  127. 128.
    Knekt P, Aromaa A, Maatela J, Alfthan G, Aaran RK, Hakama M et al. (1990) Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst 82: 864–868PubMedCrossRefGoogle Scholar
  128. 129.
    Mawson CA, Fischer MI (1952) The occurrence of zinc in the human prostate gland. Can J Med Sci 30: 336–339PubMedGoogle Scholar
  129. 130.
    Prasad AS (1995) Zinc: an overview. Nutrition 11: 93–99PubMedGoogle Scholar
  130. 131.
    Iguchi K, Hamatake M, Ishida R, Usami Y, Adachi T, Yamamoto H et al. (1998) Induction of necrosis by zinc in prostate carcinoma cells and identification of proteins increased in association with this induction. Eur J Biochem 253: 766–770PubMedCrossRefGoogle Scholar
  131. 132.
    Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P (1999) Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 40: 200–207PubMedCrossRefGoogle Scholar
  132. 133.
    Kristal AR, Stanford JL, Cohen JH, Wicklund K, Patterson RE (1999) Vitamin and mineral Supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8: 887–892PubMedGoogle Scholar
  133. 134.
    Platz EA, Helzlsouer KJ, Hoffman SC, Morris JS, Baskett CK, Comstock GW (2002) Prediagnostic toenail cadmium and zinc and subsequent prostate cancer risk. Prostate 52: 288–296PubMedCrossRefGoogle Scholar
  134. 135.
    West DW, Slattery ML, Robison LM, French TK, Mahoney AW (1991) Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control 2: 85–94PubMedCrossRefGoogle Scholar
  135. 136.
    Kolonel LN, Yoshizawa CN, Hankin JH (1988) Diet and prostatic cancer: a case-control study in Hawaii. Am J Epidemiol 127: 999–1012PubMedGoogle Scholar
  136. 137.
    Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL (2003) Zinc Supplement use and risk of prostate cancer. J Natl Cancer Inst 95: 1004–1007PubMedGoogle Scholar
  137. 138.
    Albanes D, Blair A, Taylor PR (1989) Physical activity and risk of cancer in the NHANES I population. Am J Public Health 79: 744–750PubMedCrossRefGoogle Scholar
  138. 139.
    Hartman TJ, Albanes D, Rautalahti M, Tangrea JA, Virtamo J, Stolzenberg R et al. (1998) Physical activity and prostate cancer in the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study (Finland). Cancer Causes Control 9: 11–18PubMedCrossRefGoogle Scholar
  139. 140.
    Lund Nilsen TI, Johnsen R, Vatten LJ (2000) Socio-economic and lifestyle factors associated with the risk of prostate cancer. Br J Cancer 82: 1358–1363PubMedCrossRefGoogle Scholar
  140. 141.
    Polednak AP: College athletics, body size, and cancer mortality. Cancer 38: 382–387Google Scholar
  141. 142.
    Liu S, Lee IM, Linson P, Ajani U, Buring JE, Hennekens CH (2000) A prospective study of physical activity and risk of prostate cancer in US physicians. Int J Epidemiol 29: 29–35PubMedCrossRefGoogle Scholar
  142. 143.
    Lacey JV, Jr., Deng J, Dosemeci M, Gao YT, Mostofi FK, Sesterhenn IA et al. (2001) Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China. Int J Epidemiol 30: 341–349PubMedCrossRefGoogle Scholar
  143. 144.
    Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality in relation to smoking: 40 years observations on male British doctors. Bmj 309: 901–911PubMedGoogle Scholar
  144. 145.
    Lotufo PA, Lee IM, Ajani UA, Hennekens CH, Manson JE (2000) Cigarette smoking and risk of prostate cancer in the physicians’ health study (United States). Int J Cancer 87: 141–144PubMedCrossRefGoogle Scholar
  145. 146.
    Hiatt RA, Armstrong MA, Klatsky AL, Sidney S (1994) Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States). Cancer Causes Control 5: 66–72PubMedCrossRefGoogle Scholar
  146. 147.
    Hsing AW, McLaughlin JK, Hrubec Z, Blot WJ, Fraumeni JF Jr (1991) Tobacco use and prostate cancer: 26-year follow-up of US veterans. Am J Epidemiol 133: 437–441PubMedGoogle Scholar
  147. 148.
    Coughlin SS, Neaton JD, Sengupta A (1996) Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol 143: 1002–1006PubMedGoogle Scholar
  148. 149.
    Daniell HW (1995) A worse prognosis for smokers with prostate cancel. J Urol 154: 153–157PubMedCrossRefGoogle Scholar
  149. 150.
    Roberts WW, Platz EA, Walsh PC (2003) Association of cigarette smoking with extraprostatic prostate cancer in young men. J Urol 169: 512–516; discussion 516PubMedCrossRefGoogle Scholar
  150. 151.
    Oefelein MG, Resnick MI (2004) Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer. J Urol 171: 2281–2284PubMedCrossRefGoogle Scholar
  151. 152.
    Dennis LK (2000) Meta-analysis for combining relative risks of alcohol consumption and prostate cancer. Prostate 42: 56–66PubMedCrossRefGoogle Scholar
  152. 153.
    Nomura A, Heilbrun LK, Stemmermann GN, Judd HL (1988) Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 48: 3515–3517PubMedGoogle Scholar
  153. 154.
    Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL (1990) A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 50: 169–173PubMedGoogle Scholar
  154. 155.
    Hsing AW, Comstock GW: Serological precursors of cancer (1993) serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 2: 27–32Google Scholar
  155. 156.
    Comstock GW, Gordon GB, Hsing AW (1993) The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev 2: 219–221PubMedGoogle Scholar
  156. 157.
    Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL et al. (1995) Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 27: 25–31PubMedCrossRefGoogle Scholar
  157. 158.
    Nomura AM, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk FZ (1996) Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev 5: 621–625PubMedGoogle Scholar
  158. 159.
    Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88: 1118–1126PubMedCrossRefGoogle Scholar
  159. 160.
    Guess HA, Friedman GD, Sadler MC, Stanczyk FZ, Vogelman JH, Imperato-McGinley J et al. (1997) 5 alpha-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol Biomarkers Prev 6: 21–24PubMedGoogle Scholar
  160. 161.
    Vatten LJ, Ursin G, Ross RK, Stanczyk FZ, Lobo RA, Harvei S et al. (1997) Androgens in serum and the risk of prostate cancer: nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev 6: 967–969PubMedGoogle Scholar
  161. 162.
    Dorgan JF, Albanes D, Virtamo J, Heinonen OP, Chandler DW, Galmarini M et al. (1998) Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev 7: 1069–1074PubMedGoogle Scholar
  162. 163.
    Heikkila R, Aho K, Heliovaara M, Hakama M, Marniemi J, Reunanen A et al. (1999) Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 86: 312–315PubMedCrossRefGoogle Scholar
  163. 164.
    Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB (2001) Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 57: 930–935PubMedCrossRefGoogle Scholar
  164. 165.
    Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR (2001) Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86: 724–731PubMedCrossRefGoogle Scholar
  165. 166.
    Leifke E, Gorenoi V, Wichers C, Von Zur Muhlen A, Von Buren E, Brabant G (2000) Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin Endocrinol (Oxford) 53: 689–695CrossRefGoogle Scholar
  166. 167.
    Dennis LK, Lynch CF, Torner JC (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60: 78–83PubMedCrossRefGoogle Scholar
  167. 168.
    Nelson JE, Harris RE (2000) Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7: 169–170PubMedGoogle Scholar
  168. 169.
    Clark LC, Dalkin B, Krongrad A, Combs GF, Jr., Turnbull BW, Slate EH et al. (1998) Decreased incidence of prostate cancer with selenium Supplementation: results of a double-blind cancer prevention trial. Br J Urol 81: 730–734PubMedGoogle Scholar
  169. 170.
    Dennis KK, Dawson DV (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13: 72–79PubMedCrossRefGoogle Scholar
  170. 171.
    Hayes RB, Pottern LM, Strickler H, Rabkin C, Pope V, Swanson GM et al. (2000) Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 82: 718–725PubMedCrossRefGoogle Scholar
  171. 172.
    Taylor ML, Mainous AG 3rd, Wells BJ (2005) Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 37: 506–512PubMedGoogle Scholar
  172. 173.
    Adami HO, Kuper H, Andersson SO, Bergstrom R, Dillner J (2003) Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 12: 872–875PubMedGoogle Scholar
  173. 174.
    Dillner J, Knekt P, Boman J, Lehtinen M, Af Geijersstam V, Sapp M et al. (1998) Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer 75: 564–567PubMedCrossRefGoogle Scholar
  174. 175.
    Strickler HD, Burk R, Shah K, Viscidi R, Jackson A, Pizza G et al. (1998) A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 82: 1118–1125PubMedCrossRefGoogle Scholar
  175. 176.
    Das D, Shah RB, Imperiale MJ (2004) Detection and expression of human BK virus sequences in neoplastic prostate tissues. Oncogene 23: 7031–7046PubMedCrossRefGoogle Scholar
  176. 177.
    Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP (2002) Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate 53: 263–276PubMedCrossRefGoogle Scholar
  177. 178.
    Korodi Z, Wang X, Tedeschi R, Knekt P, Dillner J (2005) No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: a nested case-control study. J Infect Dis 191: 2008–2011PubMedCrossRefGoogle Scholar
  178. 179.
    Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS (2003) High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 170: 998–1002PubMedCrossRefGoogle Scholar
  179. 180.
    Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD et al. (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274: 1371–1374PubMedCrossRefGoogle Scholar
  180. 181.
    Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ et al. (2002) Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 32: 321–325PubMedCrossRefGoogle Scholar
  181. 182.
    Dejager S, Mietus-Snyder M, Friera A, Pitas RE (1993) Dominant negative mutations of the scavenger receptor. Native receptor inactivation by expression of truncated variants. J Clin Invest 92: 894–902PubMedCrossRefGoogle Scholar
  182. 183.
    Schaid DJ, Buetow K, Weeks DE, Wijsman E, Guo SW, Ott J et al.: Discovery of cancer susceptibility genes study designs, analytic approaches, and trends in technology. J Natl Cancer Inst Monogr: (1999) 1–16Google Scholar
  183. 184.
    Seppala EH, Ikonen T, Autio V, Rokman A, Mononen N, Matikainen MP et al. (2003) Germ-line alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res 9: 5252–5256PubMedGoogle Scholar
  184. 185.
    Giles GG, Severi G, English DR, McCredie MR, Borland R, Boyle P et al. (2003) Sexual factors and prostate cancer. BJU Int 92: 211–216PubMedCrossRefGoogle Scholar
  185. 186.
    Ostrander EA, Stanford JL (2000) Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 67: 1367–1375PubMedCrossRefGoogle Scholar
  186. 187.
    Conlon EM, Goode EL, Gibbs M, Stanford JL, Badzioch M, Janer M et al. (2003) Oligogenic segregation analysis of hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onset. Int J Cancer 105: 630–635PubMedCrossRefGoogle Scholar
  187. 188.
    Gong G, Oakley-Girvan I, Wu AH, Kolonel LN, John EM, West DW et al.: Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada. Cancer Causes Control 13: 471–482Google Scholar
  188. 189.
    Verhage BA, Baffoe-Bonnie AB, Baglietto L, Smith DS, Bailey-Wilson JE, Beaty TH et al. (2001) Autosomal dominant inheritance of prostate cancer: a confirmatory study. Urology 57: 97–101PubMedCrossRefGoogle Scholar
  189. 190.
    Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN (1998) Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 62: 1425–1438PubMedCrossRefGoogle Scholar
  190. 191.
    Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 89: 3367–3371PubMedCrossRefGoogle Scholar
  191. 192.
    Gronberg H, Damber L, Damber JE, Iselius L (1997) Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 146: 552–557PubMedGoogle Scholar
  192. 193.
    Cui J, Staples MP, Hopper JL, English DR, McCredie MR, Giles GG (2001) Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet 68: 1207–1218PubMedCrossRefGoogle Scholar
  193. 194.
    Easton DF, Schaid DJ, Whittemore AS, Isaacs WJ (2003) Where are the prostate cancer genes?—A summary of eight genome wide searches. Prostate 57: 261–269PubMedCrossRefGoogle Scholar
  194. 195.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics 2003. CA Cancer J Clin 53: 5–26PubMedCrossRefGoogle Scholar
  195. 196.
    Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA et al. (2005) A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 77: 219–229PubMedCrossRefGoogle Scholar
  196. 197.
    Cooney KA, McCarthy JD, Lange E, Huang L, Miesfeldt S, Montie JE et al. (1997) Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 89: 955–959PubMedCrossRefGoogle Scholar
  197. 198.
    Hsieh CL, Oakley-Girvan I, Gallagher RP, Wu AH, Kolonel LN, Teh CZ et al. (1997) Re: prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 89: 1893–1894PubMedCrossRefGoogle Scholar
  198. 199.
    Xu J (2000) Combined analysis of hereditary prostate cancer linkage to 1q24–25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet 66: 945–957PubMedCrossRefGoogle Scholar
  199. 200.
    Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, Mononen N et al. (2002) Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 70: 1299–1304PubMedCrossRefGoogle Scholar
  200. 201.
    Wiklund F, Jonsson BA, Brookes AJ, Stromqvist L, Adolfsson J, Emanuelsson M et al. (2004) Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 10: 7150–7156PubMedCrossRefGoogle Scholar
  201. 202.
    Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A et al. (2002) A novel founder mutation in the RNASEL gene 471deIAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 71: 981–984PubMedCrossRefGoogle Scholar
  202. 203.
    Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G et al. (1998) Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 62: 1416–1424PubMedCrossRefGoogle Scholar
  203. 204.
    Cancel-Tassin G, Latil A, Valeri A, Mangin P, Fournier G, Berthon P et al. (2001) PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. Eur J Hum Genet 9: 135–142PubMedCrossRefGoogle Scholar
  204. 205.
    Berry R, Schaid DJ, Smith JR, French AJ, Schroeder JJ, McDonnell SK et al. (2000) Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1) 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet 66: 539–546PubMedCrossRefGoogle Scholar
  205. 206.
    Whittemore AS, Lin IG, Oakley-Girvan I, Gallagher RP, Halpern J, Kolonel LN et al. (1999) No evidence of linkage for chromosome 1q42.2-43 in prostate cancer. Am J Hum Genet 65: 254–256PubMedCrossRefGoogle Scholar
  206. 207.
    Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D et al. (1998) Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 20: 175–179PubMedCrossRefGoogle Scholar
  207. 208.
    Lesko SM, Rosenberg L, Shapiro S (1996) Family history and prostate cancer risk. Am J Epidemiol 144: 1041–1047PubMedGoogle Scholar
  208. 209.
    Lange EM, Chen H, Brierley K, Perrone EE, Bock CH, Gillanders E et al. (1999) Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin Cancer Res 5: 4013–4020PubMedGoogle Scholar
  209. 210.
    Peters MA, Jarvik GP, Janer M, Chakrabarti L, Kolb S, Goode EL et al. (2001) Genetic linkage analysis of prostate cancer families to Xq27-28. Hum Hered 51: 107–113PubMedCrossRefGoogle Scholar
  210. 211.
    Farnham JM, Camp NJ, Swensen J, Tavtigian SV, Albright LA (2005) Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees. Hum Genet 116: 179–185PubMedCrossRefGoogle Scholar
  211. 212.
    Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A et al. (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 27: 172–180PubMedCrossRefGoogle Scholar
  212. 213.
    Camp NJ, Tavtigian SV (2002) Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer. Am J Hum Genet 71: 1475–1478PubMedCrossRefGoogle Scholar
  213. 214.
    Severi G, Giles GG, Southey MC, Tesoriero A, Tilley W, Neufing P et al. (2003) ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. J Natl Cancer Inst 95: 818–824PubMedCrossRefGoogle Scholar
  214. 215.
    Cunningham JM, McDonnell SK, Marks A, Hebbring S, Anderson SA, Peterson BJ et al. (2003) Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study. Prostate 57: 335–346PubMedCrossRefGoogle Scholar
  215. 216.
    Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM et al. (2000) Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 67: 82–91PubMedCrossRefGoogle Scholar
  216. 217.
    Bock CH, Cunningham JM, McDonnell SK, Schaid DJ, Peterson BJ, Pavlic RJ et al. (2001) Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer. Am J Hum Genet 68: 795–801PubMedCrossRefGoogle Scholar
  217. 218.
    Zheng SL, Xu J, Isaacs SD, Wiley K, Chang B, Bleecker ER et al. (2001) Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. Hum Genet 108: 430–435PubMedCrossRefGoogle Scholar
  218. 219.
    Schaid DJ, Chang BL (2005) Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13. Prostate 63: 276–290PubMedCrossRefGoogle Scholar
  219. 220.
    Xu J, Gillanders EM, Isaacs SD, Chang BL, Wiley KE, Zheng SL et al. (2003) Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. Prostate 57: 320–325PubMedCrossRefGoogle Scholar
  220. 221.
    Janer M, Friedrichsen DM, Stanford JL, Badzioch MD, Kolb S, Deutsch K et al. (2003) Genomic scan of 254 hereditary prostate cancer families. Prostate 57: 309–319PubMedCrossRefGoogle Scholar
  221. 222.
    Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD et al. (2001) Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22–23. Am J Hum Genet 69: 341–350PubMedCrossRefGoogle Scholar
  222. 223.
    Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Chang B et al. (2003) Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet 72: 208–212PubMedCrossRefGoogle Scholar
  223. 224.
    Hawkins GA, Mychaleckyj JC, Zheng SL, Faith DA, Kelly B, Isaacs SD et al. (2002) Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk. Cancer Genet Cytogenet 137: 1–7PubMedCrossRefGoogle Scholar

Literatur zu Kap. 2.2.1, 2.2.3 und 2.2.4

  1. 1.
    Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA, Jr. (2006) Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98: 529–534PubMedCrossRefGoogle Scholar
  2. 2.
    Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA, Jr. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350: 2239–2246PubMedCrossRefGoogle Scholar
  3. 3.
    Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822–826PubMedCrossRefGoogle Scholar
  4. 4.
    Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811–816PubMedCrossRefGoogle Scholar
  5. 5.
    Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790–2799PubMedCrossRefGoogle Scholar
  6. 6.
    Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41–51PubMedCrossRefGoogle Scholar
  7. 7.
    Schlomm T, Hellwinkel OJ, Buness A, Ruschhaupt M, Lubke AM, Chun FK, Simon R, Budaus L, Erbersdobler A, Graefen M, Huland H, Poustka A, Sultmann H (2008) Molecular Cancer Phenotype in Normal Prostate Tissue. Eur UrolGoogle Scholar
  8. 8.
    Schlomm T, Luebke AM, Sultmann H, Hellwinkel OJ, Sauer U, Poustka A, David KA, Chun FK, Haese A, Graefen M, Erbersdobler A, Huland H (2005) Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis. Int J Oncol 27: 713–720PubMedGoogle Scholar
  9. 9.
    Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644–648PubMedCrossRefGoogle Scholar
  10. 10.
    Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA (2008) Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 14: 3380–3385PubMedCrossRefGoogle Scholar
  11. 11.
    Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP (1995) Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55: 342–347PubMedGoogle Scholar
  12. 12.
    Kamradt J, Jung V, Wahrheit K, Tolosi L, Rahnenfuehrer J, Schilling M, Walker R, Davis S, Stoeckle M, Meltzer P, Wullich B (2007) Detection of novel amplicons in prostate cancer by comprehensive genomic profiling of prostate cancer cell lines using oligonucleotide-based arrayCGH. PloS ONE 2: e769PubMedCrossRefGoogle Scholar
  13. 13.
    Morris DS, Tomlins SA, Montie JE, Chinnaiyan AM (2008) The discovery and application of gene fusions in prostate cancer. BJU IntGoogle Scholar
  14. 14.
    Buness A, Kuner R, Ruschhaupt M, Poustka A, Sultmann H, Tresch A (2007) Identification of aberrant chromosomal regions from gene expression microarray studies applied to human breast cancer. Bioinformatics 23: 2273–2280PubMedCrossRefGoogle Scholar
  15. 15.
    Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhoffer M, Laurberg S, Borre M, Wang K, Brunak S, Krainer AR, Torring N, Dyrskjot L, Andersen CL, Orntoft TF (2008) Alternative splicing in colon, bladder, and prostate cancer identified by exon-array analysis. Mol Cell ProteomicsGoogle Scholar
  16. 16.
    Loebke C, Sueltmann H, Schmidt C, Henjes F, Wiemann S, Poustka A, Korf U (2007) Infrared-based protein detection arrays for quantitative proteomics. Proteomics 7: 558–564PubMedCrossRefGoogle Scholar
  17. 17.
    Miller JC, Zhou H, Kwekel J, Cavallo R, Burke J, Butler EB, Teh BS, Haab BB (2003) Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3: 56–63PubMedCrossRefGoogle Scholar
  18. 18.
    Haller F, Lobke C, Ruschhaupt M, Cameron S, Schulten HJ, Schwager S, von Heydebreck A, Gunawan B, Langer C, Ramadori G, Sultmann H, Poustka A, Korf U, Fuzesi L (2008) Loss of 9p leads to p16(INK4A) down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). J Pathol 215: 253–262PubMedCrossRefGoogle Scholar
  19. 19.
    Chun FK, Karakiewicz PI, Huland H, Graefen M (2007) Role of nomograms for prostate cancer in 2007. World J Urol 25: 131–142PubMedCrossRefGoogle Scholar
  20. 20.
    Fleischmann A, Schlomm T, Huland H, Kollermann J, Simon P, Mirlacher M, Salomon G, Chun FH, Steuber T, Simon R, Sauter G, Graefen M, Erbersdobler A (2008) Distinct subcellular expression patterns of neutral endopeptidase (CD 10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 14: 7838–7842PubMedCrossRefGoogle Scholar
  21. 21.
    Kollermann J, Schlomm T, Bang H, Schwall GP, von Eichel-Streiber C, Simon R, Schostak M, Huland H, Berg W, Sauter G, Klocker H, Schrattenholz A (2008) Expression and prognostic relevance of annexin a3 in prostate cancer. Eur Urol 54: 1314–1323PubMedCrossRefGoogle Scholar
  22. 22.
    Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod PatholGoogle Scholar
  23. 23.
    Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Chun FH, Haese A, Kollermann J, Graefen M, Huland H, Sauter G, Simon R, Erbersdobler A (2007) Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 13: 6579–6584PubMedCrossRefGoogle Scholar
  24. 24.
    Schlomm T, Erbersdobler A, Mirlacher M, Sauter G (2007) Molecular staging of prostate cancer in the year 2007. World J Urol 25: 19–30PubMedCrossRefGoogle Scholar

Literatur zu Kap. 25.2.2

  1. 1.
    Randolph TL, Amin MB, Ro JY, Ayala AG (1997) Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Mod Pathol 10: 612–629PubMedGoogle Scholar
  2. 2.
    Grignon DJ (2004) Unusual subtypes of prostate cancer. Mod Pathol 17: 316–327PubMedCrossRefGoogle Scholar
  3. 3.
    Ro JY, Grignon DJ, Ayala AG, Fernandez PL, Ordonez NG, Wishnow KI (1990) Mucinous adenocarcinoma of the prostate: histochemical and immunohistochemical studies. Hum Pathol 21: 593–600PubMedCrossRefGoogle Scholar
  4. 4.
    Parwani AV, Kronz JD, Genega EM, Gaudin P, Chang S, Epstein JI (2004) Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am J Surg Pathol 28: 651–657PubMedGoogle Scholar
  5. 5.
    Shannon RL, Ro JY, Grignon DJ, Ordonez NG, Johnson DE, Mackay B, Tetu B, Ayala AG (1992) Sarcomatoid carcinoma of the prostate. A clinicopathologic study of 12 patients. Cancer 69: 2676–2682PubMedCrossRefGoogle Scholar
  6. 6.
    Helpap B, Kollermann J (1999) Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 434: 385–391PubMedCrossRefGoogle Scholar
  7. 7.
    Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Longterm biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28: 555–565PubMedCrossRefGoogle Scholar
  8. 8.
    Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. Jama 277: 1445–1451PubMedCrossRefGoogle Scholar
  9. 9.
    Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50: 125–128PubMedGoogle Scholar
  10. 10.
    Epstein JI (1996) The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens. Cancer 78: 350–356PubMedCrossRefGoogle Scholar
  11. 11.
    Epstein JI, Partin AW, Sauvageot J, Walsh PC (1996) Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20: 286–292PubMedCrossRefGoogle Scholar
  12. 12.
    Epstein JI, Allsbrook WC, Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29: 1228–1242PubMedCrossRefGoogle Scholar
  13. 13.
    Amin M, Boccon-Gibod L, Egevad L, Epstein JL, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R (2005) Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl 20-33Google Scholar
  14. 14.
    Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC, Jr. (2003) The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 98: 2344–2350PubMedCrossRefGoogle Scholar
  15. 15.
    Kartan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, Shariat SF, Slawin KM, Ohori M (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170: 1792–1797CrossRefGoogle Scholar
  16. 16.
    Freedland SJ, Csathy GS, Dorey F, Aronson WJ (2002) Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 167: 516–520PubMedCrossRefGoogle Scholar
  17. 17.
    Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW (2003) Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology 61: 589–595PubMedCrossRefGoogle Scholar
  18. 18.
    Koh H, Kattan MW, Scardino PT, Suyama K, Maru N, Slawin K, Wheeler TM, Ohori M (2003) A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 170: 1203–1208PubMedCrossRefGoogle Scholar
  19. 19.
    Anderson PR, Hanlon AL, Patchefsky A, Al-Saleem T, Hanks GE (1998) Perineural invasion and Gleason 7–10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 41: 1087–1092PubMedGoogle Scholar
  20. 20.
    Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, D’Amico AV (2004) Perineural invasion is associated with increased relapse after external beam radiotherapy for men with lowrisk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys 58: 19–24PubMedCrossRefGoogle Scholar
  21. 21.
    Quinn DI, Henshall SM, Brenner PC, Kooner R, Golovsky D, O’Neill GF, Turner JJ, Delprado W, Grygiel JJ, Sutherland RL, Stricker PD (2003) Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer 97: 1884–1893PubMedCrossRefGoogle Scholar
  22. 22.
    Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, Blute ML, Zincke H (2001) Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 91: 2196–2204PubMedCrossRefGoogle Scholar
  23. 23.
    Vargas SO, Jiroutek M, Welch WR, Nucci MR, D’Amico AV, Renshaw AA (1999) Perineural invasion in prostate needle biopsy specimens. Correlation with extraprostatic extension at resection. Am J Clin Pathol 111: 223–228PubMedGoogle Scholar
  24. 24.
    van den Ouden D, Hop WC, Kranse R, Schroder FH (1997) Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol 79: 203–211PubMedGoogle Scholar
  25. 25.
    de la Taille A, Rubin MA, Buttyan R, Olsson CA, Bagiella E, Burchardt M, Wellisch OM, Katz AE (2000) Is microvascular invasion on radical prostatectomy specimens a useful predictor of PSA recurrence for prostate cancer patients? Eur Urol 38: 79–84PubMedCrossRefGoogle Scholar
  26. 26.
    McNeal JE, Yemoto CE (1996) Significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma. Am J Surg Pathol 20: 1351–1360PubMedCrossRefGoogle Scholar
  27. 27.
    Epstein JI, Herawi M (2006) Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 175: 820–834PubMedCrossRefGoogle Scholar
  28. 28.
    Iczkowski KA, Bassler TJ, Schwob VS, Bassler IC, Kunnel BS, Orozco RE, Bostwick DG (1998) Diagnosis of “suspicious for malignancy” in prostate biopsies: predictive value for cancer. Urology 51: 749–757; discussion 757–748PubMedCrossRefGoogle Scholar
  29. 29.
    Iczkowski KA, MacLennan GT, Bostwick DG (1997) Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol 21: 1489–1495PubMedCrossRefGoogle Scholar
  30. 30.
    Epstein JI, Potter SR (2001) The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol 166: 402–410PubMedCrossRefGoogle Scholar
  31. 31.
    Helpap B, Kollermann J, Oehler U (2001) Limiting the diagnosis of atypical small glandular proliferations in needle biopsies of the prostate by the use of immunohistochemistry. J Pathol 193: 350–353PubMedCrossRefGoogle Scholar
  32. 32.
    Epstein JI, Pizov G, Walsh PC (1993) Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582–3593PubMedCrossRefGoogle Scholar
  33. 33.
    Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, Ohori M, Scardino PT (1998) Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 29: 856–862PubMedCrossRefGoogle Scholar
  34. 34.
    Epstein JI, Partin AW, Potter SR, Walsh PC (2000) Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology 56: 283–288PubMedCrossRefGoogle Scholar
  35. 35.
    Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R (2005) Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 34–63Google Scholar
  36. 36.
    Epstein JI (1990) Evaluation of radical prostatectomy capsular margins of resection. The significance of margins designated as negative, closely approaching, and positive. Am J Surg Pathol 14: 626–632PubMedCrossRefGoogle Scholar
  37. 37.
    Epstein JI, Sauvageot J (1997) Do close but negative margins in radical prostatectomy specimens increase the risk of postoperative progression? J Urol 157: 241–243PubMedCrossRefGoogle Scholar
  38. 38.
    Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT (1995) Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154: 1818–1824PubMedCrossRefGoogle Scholar
  39. 39.
    Babaian RJ, Troncoso P, Bhadkamkar VA, Johnston DA (2001) Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 91: 1414–1422PubMedCrossRefGoogle Scholar
  40. 40.
    Freedland SJ, Aronson W, Presti JC, Jr, Kane CJ, Terris MK, Elashoff D, Amling CL (2003) Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J Urol 169: 2142–2146PubMedCrossRefGoogle Scholar
  41. 41.
    Kupelian P, Katcher J, Levin H, Zippe C, Klein E (1996) Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48: 249–260PubMedCrossRefGoogle Scholar
  42. 42.
    Salomon L, Anastasiadis AG, Antiphon P, Levrel O, Saint F, De la Taille A, Cicco A, Vordos D, Hoznek A, Chopin D, Abbou CC (2003) Prognostic consequences of the location of positive surgical margins in organ-confined prostate cancer. Urol Int 70: 291–296PubMedCrossRefGoogle Scholar
  43. 43.
    Watson RB, Civantos F, Soloway MS (1996) Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology 48: 80–90PubMedCrossRefGoogle Scholar
  44. 44.
    Weldon VE, Tavel FR, Neuwirth H, Cohen R (1995) Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 153: 1565–1569PubMedCrossRefGoogle Scholar
  45. 45.
    D’Amico AV, Whittington R, Malkowicz SB, Loughlin K, Schultz D, Schnall M, Tempany CM, Tomaszewski JE, Renshaw A, Wein A (1996) An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy. Urology 47: 538–547PubMedCrossRefGoogle Scholar
  46. 46.
    Augustin H, Hammerer PG, Blonski J, Graefen M, Palisaar J, Daghofer F, Huland H, Erbersdobler A (2003) Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy. Urology 62: 79–85PubMedCrossRefGoogle Scholar
  47. 47.
    McNeal JE (1992) Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 23: 258–266PubMedCrossRefGoogle Scholar
  48. 48.
    Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM (1999) Biological determinants of cancer progression in men with prostate cancer. JAMA 281: 1395–1400PubMedCrossRefGoogle Scholar
  49. 49.
    Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P (2003) A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 27: 1291–1301PubMedCrossRefGoogle Scholar
  50. 50.
    Humphrey PA, Vollmer RT (1997) Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 10: 326–333PubMedGoogle Scholar
  51. 51.
    Noguchi M, Stamey TA, McNeal JE, Yemoto CE (2000) Assessment of morphometric measurements of prostate carcinoma volume. Cancer 89: 1056–1064PubMedCrossRefGoogle Scholar
  52. 52.
    Renshaw AA, Chang H, D’Amico AV (1997) Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. Am J Clin Pathol 107: 704–708PubMedGoogle Scholar
  53. 53.
    Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D’Amico AV (1999) Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens. Validation in a cohort of 434 patients. Am J Clin Pathol 111: 641–644PubMedGoogle Scholar
  54. 54.
    Wise AM, Stamey TA, McNeal JE, Clayton JL (2002) Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60: 264–269PubMedCrossRefGoogle Scholar
  55. 55.
    Carvalhal GF, Humphrey PA, Thorson P, Yan Y, Ramos CG, Catalona WJ (2000) Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer 89: 1308–1314PubMedCrossRefGoogle Scholar
  56. 56.
    Ramos CG, Roehl KA, Antenor JA, Humphrey PA, Catalona WJ (2004) Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol 172: 137–140PubMedCrossRefGoogle Scholar
  57. 57.
    Ohori M, Abbas F, Wheeler TM, Kattan MW, Scardino PT, Lerner SP (1999) Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol 161: 500–504PubMedCrossRefGoogle Scholar
  58. 58.
    Palisaar RJ, Graefen M, Karakiewicz PI, Hammerer PG, Huland E, Haese A, Fernandez S, Erbersdobler A, Henke RP, Huland H (2002) Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer. Eur Urol 41: 155–161PubMedCrossRefGoogle Scholar
  59. 59.
    Salomon L, Levrel O, Anastasiadis AG, Irani J, De La Taille A, Saint F, Vordos D, Cicco A, Hoznek A, Chopin D, Abbou CC (2003) Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 43: 39–44PubMedCrossRefGoogle Scholar
  60. 60.
    Chun FKH, Briganti A, Jeldres C, Gallina A, Erbersdobler A, Schlomm T, Currlin E, Ahyai SA, Salomon G, Isbarn H, Walz J, Eichelberg C, Steuber T, Haese A, Heinzer H, Bénard F, Huland H, Graefen M, Pi K (2007) Tumor volume and high grade tumor volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. ASCO Prostata Cancer Symposium, abstract 329Google Scholar
  61. 61.
    Ravery V, Boccon-Gibod LA, Meulemans A, Dauge-Geffroy MC, Toublanc M, Boccon-Gibod L (1994) Predictive value of pathological features for progression after radical prostatectomy. Eur Urol 26: 197–201PubMedGoogle Scholar
  62. 62.
    Endrizzi J, Seay T (2000) The relationship between early biochemical failure and perineural invasion in pathological T2 prostate cancer. BJU Int 85: 696–698PubMedCrossRefGoogle Scholar
  63. 63.
    Ito K, Nakashima J, Mukai M, Asakura H, Ohigashi T, Saito S, Tachibana M, Hata J, Murai M (2003) Prognostic implication of microvascular invasion in biochemical failure in patients treated with radical prostatectomy. Urol Int 70: 297–302PubMedCrossRefGoogle Scholar
  64. 64.
    Ng JC, Koch MO, Daggy JK, Cheng L (2004) Perineural invasion in radical prostatectomy specimens: lack of prognostic significance. J Urol 172: 2249–2251PubMedCrossRefGoogle Scholar
  65. 65.
    Merrilees AD, Bethwaite PB, Russell GL, Robinson RG, Delahunt B (2008) Parameters of perineural invasion in radical prostatectomy specimens lack prognostic significance. Mod PatholGoogle Scholar
  66. 66.
    Schlomm T, Borgermann C, Heinzer H, Rubben H, Huland H, Graefen M (2008) Role of lymphnode dissection in prostate cancer. Urologe A (in print)Google Scholar
  67. 67.
    Cheng L, Slezak J, Bergstralh EJ, Cheville JC, Sweat S, Zincke H, Bostwick DG (1999) Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer 86: 657–663PubMedCrossRefGoogle Scholar
  68. 68.
    Sgrignoli AR, Walsh PC, Steinberg GD, Steiner MS, Epstein JI (1994) Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol 152: 1077–1081PubMedGoogle Scholar
  69. 69.
    Steinberg GD, Epstein JI, Piantadosi S, Walsh PC (1990) Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol 144: 1425–1432PubMedGoogle Scholar
  70. 70.
    Cheng L, Bergstralh EJ, Cheville JC, Slezak J, Corica FA, Zincke H, Blute ML, Bostwick DG (1998) Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 22: 1491–1500PubMedCrossRefGoogle Scholar
  71. 71.
    Griebling TL, Ozkutlu D, See WA, Cohen MB (1997) Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer. Mod Pathol 10: 804–809PubMedGoogle Scholar
  72. 72.
    Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schroder FH, Wildhagen MF, Scardino PT, Kattan MW (2002) Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 20: 951–956PubMedCrossRefGoogle Scholar
  73. 73.
    Kattan MW, Wheeler TM, Scardino PT (1999) Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17: 1499–1507PubMedGoogle Scholar

Literatur zu Kap. 25.3

  1. American Cancer Society (2005) Cancer Facts & Figures. www.cancer. org/downloads/STT/CAFF2005f4PW Secured.pdfGoogle Scholar
  2. Aus G, Hugosson J, Norlen L (1995) Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 154: 460–465PubMedCrossRefGoogle Scholar
  3. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH (1992) The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817–821PubMedGoogle Scholar
  4. Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W (2005) Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64:240–245PubMedCrossRefGoogle Scholar
  5. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C et al. (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100(16):1144–1154PubMedCrossRefGoogle Scholar
  6. Blanc M, Sacrini A, Avogadro A, Gattamorta M, Lazzerini F, Gattoni F, Cretti F (1998) Prostatic volume: suprapubic, versus transrectal ultrasonography in the control of benign prostatic hyperplasia. Radiol Med 95: 182–187PubMedGoogle Scholar
  7. Brawer M. K, Cheli CD, Neaman I.E., Goldblatt J, Smith C, Schwartz MK, Bruzek DJ, Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ (2000) Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 163: 1476–1480PubMedCrossRefGoogle Scholar
  8. Brawer MK, Chetner MP (1997) In: Walsh PC, Retik A, Stamey TA, Vaughan EJ (eds) Campell’s urology, 7th edn. Saunders, Philadelphia, pp 2506–2518Google Scholar
  9. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD (1997) Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 277(18): 1456–1460PubMedCrossRefGoogle Scholar
  10. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI et al. (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98(21): 1521–1527PubMedCrossRefGoogle Scholar
  11. Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein JI, Walsh PC (1989) Evaluation of transrectal ultrasound in the early detection of prostate cancer. J Urol 142: 1008–1010PubMedGoogle Scholar
  12. Carter HB, Pearson JD (1993) PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am 20: 665–670PubMedGoogle Scholar
  13. Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ (1999) Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol 161: 835–839PubMedCrossRefGoogle Scholar
  14. Catalona W.J, Partin AW, Slawin KM et al. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279: 1542–1547PubMedCrossRefGoogle Scholar
  15. Catalona WJ, Loeb S (2005) The PSA era is not over for prostate cancer. Eur Urol 48: 541–545PubMedCrossRefGoogle Scholar
  16. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al. (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279(19): 1542–1547PubMedCrossRefGoogle Scholar
  17. Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organconfined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948–954PubMedCrossRefGoogle Scholar
  18. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB (1995) Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214–1220PubMedCrossRefGoogle Scholar
  19. Collins GN, Lloyd SN, Hehir M, McKelvie GB (1993) Multiple transrectal ultrasound-guided prostatic biopsies-true morbidity and patient acceptance. Br J Urol 71: 460–463PubMedCrossRefGoogle Scholar
  20. De Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE (2002) Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 98: 268–273PubMedCrossRefGoogle Scholar
  21. Eggert T, Khaled W, Wenske S, Ermert H, Noldus J (2008) Impact of elastography in clinical diagnosis of prostate cancer. A comparison of cancer detection between B-mode sonography and elastography-guided 10-core biopsies Urologe A 47(9): 1212–1217PubMedCrossRefGoogle Scholar
  22. Ellis WJ, Chetner MP, Preston SD, Brawer MK (1994) Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 152: 1520–1525PubMedGoogle Scholar
  23. Fachgesellschaften (2002) Arbeitsgemeinschaft wissenschaftlich medizinischer Fachgesellschaften. S3-Leitlinie: PSA-Bestimmung in der Prostatakarzinomdiagnostik (Früherkennung des Prostatakarzinoms). www.awmf-online.de. 2002Google Scholar
  24. Flanigan RC, Catalona WJ, Richie JP et al. (1994) Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol 152: 1506–1509PubMedGoogle Scholar
  25. Gann PH, Hennekens CH, Stampfer MJ (1995) A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273: 289–294PubMedCrossRefGoogle Scholar
  26. Hoedemaeker RF, Rietbergen JB, Kranse R, Schroder FH, van der Kwast TH (2000) Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol 164: 411–415PubMedCrossRefGoogle Scholar
  27. Klotz L (2004) Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172: S48–S50PubMedCrossRefGoogle Scholar
  28. Lilja H (2001) Role of hK2: free PSA, and complexed PSA measurements in the very early detection of prostate cancer. Eur Urol 39 Suppl 4: 47–48PubMedCrossRefGoogle Scholar
  29. Loch T, Eppelmann U, Lehmann J, Wullich B, Loch A, Stockle M (2004) Transrectal ultrasound guided biopsy of the prostate: random sextant versus biopsies of sono-morphologically suspicious lesions. World J Urol 22: 357–360PubMedCrossRefGoogle Scholar
  30. Loch T, Leuschner I, Genberg C, Weichert-Jacobsen K, Kuppers F, Retz M, Lehmann J, Yfantis E, Evans M, Tsarev V, Stockle M (2000) Improvement of transrectal ultrasound. Artificial neural network analysis (ANNA) in detection and staging of prostatic carcinoma. Urologe A 39: 341–347PubMedCrossRefGoogle Scholar
  31. Loeb S, Roehl KA, Catalona WJ, Nadler RB (2007) Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 177(3): 899–902PubMedCrossRefGoogle Scholar
  32. Luboldt H, Rübben H (2000) PSA — Fruherkennung des Prostatakarzinoms. Urologe A 39: 22–26PubMedCrossRefGoogle Scholar
  33. Luboldt HJ, Altwein JE, Bichler KH et al. (1999) Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle. Urologe A 38: 114–123PubMedCrossRefGoogle Scholar
  34. Luboldt HJ, Husing J, Altwein JE et al. (2000) Early detection of prostatic carcinoma in urologic practice with digital rectal examination and prostate-specific antigen. Early Detection Project Group. Urologe A 39: 330–333PubMedCrossRefGoogle Scholar
  35. Nagler HM, Gerber EW, Homel P, Wagner JR, Norton J, Lebovitch S, Phillips JL (2005) Digital rectal examination is barrier to population-based prostate cancer screening. Urology 65: 1137–1140PubMedCrossRefGoogle Scholar
  36. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser L. A, Lieber MM (1993) Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860–864PubMedCrossRefGoogle Scholar
  37. Pienta KJ (1997) Etiology epidemiology and prevention of carcinoma of the prostate. In: Walsh PC, Retik A, Stamey TA, Vaughan EJ (eds) Campell’s urology, 7th edn. Saunders, Philadelphia, pp 2489–2496Google Scholar
  38. Potter SR, Carter HB (2000) The role of prostate-specific antigen velocity in prostate cancer early detection. Curr Urol Rep 1: 15–19PubMedCrossRefGoogle Scholar
  39. Price CP, Allard J, Davies G, Dawnay A, Duffy MJ, France M, Mandarino G, Ward AM, Patel B, Sibley P, Sturgeon C (2001) Pre-and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 38: 188–216PubMedCrossRefGoogle Scholar
  40. Remzi M, Fong YK, Dobrovits M, Anagnostou T, Seitz C, Waldert M et al. (2005) The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 174(4 Pt 1): 1256–1260PubMedCrossRefGoogle Scholar
  41. Roehrborn CG, Sech S, Montoya J, Rhodes T, Girman CJ (2001) Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination. Urology 57: 1087–1092PubMedCrossRefGoogle Scholar
  42. Roobol MJ, Roobol DW, Schroder FH (2005) Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65: 343–346PubMedCrossRefGoogle Scholar
  43. Schmid HP, Riesen W, Prikler L (2004) Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 50: 71–78PubMedCrossRefGoogle Scholar
  44. Schroder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH et al. (2008) Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 53(3): 468–477PubMedCrossRefGoogle Scholar
  45. Schröder FH, Roobol-Bouts M, Vis AN, van der KT, Kranse R (2001) Prostate-specific antigen-based early detection of prostate cancer — validation of screening without rectal examination. Urology 57: 83–90PubMedCrossRefGoogle Scholar
  46. Schröder FH, Van DC-KI De Koning HJ, Vis AN, Hoedemaeker RF, Kranse R (2000) Prostate cancer detection at low prostate specific antigen. J Urol 163: 806–812PubMedCrossRefGoogle Scholar
  47. Smith DS, Catalona WJ (1995) Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 45: 70–74PubMedCrossRefGoogle Scholar
  48. Stamey T. A., Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J (2004) The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172: 1297–1301PubMedCrossRefGoogle Scholar
  49. Statistisches Bundesamt (2009) www.destatis.de/basis/d/gesu/gesutab20.phpGoogle Scholar
  50. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O (1991) A complex between prostate-specific antigen and alpha 1-anticymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51(1): 222–226PubMedGoogle Scholar
  51. Van der Crujisen-Koeter IW van der Kwast TH, Schroder FH (2003) Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 95: 1462–1466Google Scholar
  52. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE (1998) A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 159: 920–924PubMedCrossRefGoogle Scholar
  53. Vis AN, Kranse R, Roobol M, van der Kwast TH, Schroder FH (2002) Serendipity in detecting disease in low prostate-specific antigen ranges. BJU Int 89: 384–389PubMedCrossRefGoogle Scholar
  54. Walsh PC, Partin AW, Epstein JI (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152: 1831–1836PubMedGoogle Scholar

Literatur zu Kap. 25.4

  1. Altwein JE (1994) Is hormone therapy indicated in localised carcinoma of the prostate? In: Murphy G, Khoury S, Chatelain C, Denis I (eds) 4th International Symposium on Recent Advances in Urological Cancer. S.C.I. Jersey, pp 293Google Scholar
  2. Alves PM, Faure O, Graff-Dubois S et al. (2006) STEAP, a prostate tumor antigen, is a target of human CD8 (+) T cells. Cancer Immunol Immunother. Cancer Immunol Immunother 55(12): 1515–1523PubMedCrossRefGoogle Scholar
  3. American Society for Clinical Oncology (2003) American Cancer Society Guidelines 53: 27–43Google Scholar
  4. Andriole GI, Kavoussi LR, Torrence RJ et al. (1988) Transrectal ultrasonography in the diagnosis and staging of carcinoma of the prostate. J Urol 140: 758–760PubMedGoogle Scholar
  5. Ayala GE, Dai H, Li R et al. (2006) Bystin in perineural invasion of prostate cancer. Prostate 66: 266–272PubMedCrossRefGoogle Scholar
  6. Babaian RJ, Mettlin C, Krane R et al. (1992) The relationship of prostatespecific antigen to digital rectal examination and transrectal ultrasogography. Cancer 69(5): 1195–1200PubMedGoogle Scholar
  7. Babaian RJ, Naya Y, Cheli C (2006) The detection and potential economic value of complexed prostate specific antigen as a first line test. J Urol 175: 897–901; discussion 901PubMedCrossRefGoogle Scholar
  8. Bazinet M, Karakiewitz PI, Aprikian AG et al. (1996) Value of systematic transition zone biopsies in the early detection of prostate cancer. J Urol 155: 605–6PubMedCrossRefGoogle Scholar
  9. Becker n (2002) Epidemiologie. In: Höffken K, Kolb G, Wedding U (Hrsg) Geriatrische Onkologie. Springer, Berlin Heidelberg New York Tokio, S. 1–28Google Scholar
  10. Beheshti M, Vali R, Waldenberger P et al. (2008) Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 35(10): 1766–74PubMedCrossRefGoogle Scholar
  11. Benechi L (2006) PSA velocity and PSA slope. Prostate Cancer Prostatic Dis 9: 169–172CrossRefGoogle Scholar
  12. Benson MC, Whang IS, Pantuck A et al. (1992) Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147: 815–6PubMedGoogle Scholar
  13. Björk T, Hulkko S, Bjartell A et al. (1994) Alpha-1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urol 43: 427–437PubMedCrossRefGoogle Scholar
  14. Borgermann C, Sieverding M, Fornara P et al. (2006) PSA 2010 — Aufbruch in eine neue Ära der Früherkennung des Prostatakarzinom. Urologe A (Suppl 4): 127–133Google Scholar
  15. Bombardieri EE (1990) Zirkulierende Tumormarker beim Prostatakarzinom. In Staehler G, Fabricius PG: Das Prostatakarzinom. Springer, Berlin, pp 9–20Google Scholar
  16. Bressel M (1989) Radikale retropubische Prostatektomie (RRP). In: Sommerkamp H, Altwein JE (Hrsg) Prostatakarzinom — Spektrum der kurativen Therapie. Karger, Basel, S 146–173Google Scholar
  17. Bretan PN, Williams RD (1987) Imaging techniques in the diagnosis und pelvic stging of prostatic cancer. In: Bruce AW, Trachtenberg J (eds) Adenocarcinoma of the prostate. Springer, Berlin Heidelbeg, New York, pp 83–106Google Scholar
  18. Bundesärztekammer (2003) Mitteilungen: Richtlinie der Bundesärztekammer zur Qualitätssicherung quantitativer laboratoriumsmedizinischer Untersuchungen. Deutsches Ärzteblatt 100, Ausgabe 50, Seite A-3335/B-2775/C-2595 (Anlage 1a-d)Google Scholar
  19. Carter HB, Partin AW, Luderer AA et al. (1997) Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 49: 379–384PubMedCrossRefGoogle Scholar
  20. Carter HB, Ferrucci L, Metter JE (2005) PSA velocity and risk of prostate cancer death in the Baltimore longitudinal study of aging. AUA Abstract 951Google Scholar
  21. Cartledge JJ, Thompson D, Verril H et al. (1999) The stability of free and bound prostate-specific antigen. BJU Int 84: 810–814PubMedCrossRefGoogle Scholar
  22. Catalona WJ, Partin AW, Slawin KM et al. (1997) A multicenter clinical trial evaluation of free PSA in the differentiation of prostate cancer from benign disease. J Urol 157: 111Google Scholar
  23. Catalona WJ, Smith DS, Wolfert RL et al. (1995) Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214–1220PubMedCrossRefGoogle Scholar
  24. Clements J, Muktar A (1994) Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocr Metab 78: 1536PubMedCrossRefGoogle Scholar
  25. Clements R (2002) The role of transrectal ultrasound in diagnosing prostate cancer. Curr Urol Rep 3: 194–200PubMedCrossRefGoogle Scholar
  26. Coley CM, Barry MJ, Fleming C et al. (1997) Early detection of prostate cancer. Ann Intern Med 126: 394–406PubMedGoogle Scholar
  27. Cooner EH, Mosley BR, Rutherford CL JR et al. (1990) Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectalexamination and prostate specific antigen. J Urol 143: 1146–1154PubMedGoogle Scholar
  28. Cooner WH (1993) Prostate-specific antigen coordinated with digital rectal examination and transrectal ultrasonography in the detection of prostate cancer. World J Urol 11: 214–7PubMedCrossRefGoogle Scholar
  29. Cornud F, Berllin MF, Portalez D. (2006) MRI and staging evaluation of prostate cancer. J Radiol 87: 228–43PubMedCrossRefGoogle Scholar
  30. Curiel L, Souchon R, Rouvière O et al. (2005) Elastography for the follow-up of high-intensity focused ultrasound prostate cancer treatment: initial comparison with MRI. Ultrasound Med Biol 31(11): 1461–68PubMedCrossRefGoogle Scholar
  31. D’Amico AV, Cullen J, Chen Y et al. (2006) Prostate-Specific Antigen Velocity and the Odds of Identifying Prostate Cancer at Biopsy. AUA: 523Google Scholar
  32. D’Amico AV, Renshaw AA, Sussman B et al. (2005) Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294: 440–7PubMedCrossRefGoogle Scholar
  33. Djavan B, Milani S, Remzi M (2005) Prostate biopsy: who, how and when. An update. Can J Urol 12 Suppl 1: 44–8; discussion 99–100PubMedGoogle Scholar
  34. Djavan B, Waldert M, Zlotta A (2001) Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 166: 856–60PubMedCrossRefGoogle Scholar
  35. Eggener SE, Roehl KA, Catalona WJ. (2005) Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2,6 to 4,0 ng/ml and an initially negative biopsy. Urol 174: 500–504CrossRefGoogle Scholar
  36. Ekici S, Ozen H, Agildere M (1999) A comparison of transrectal ultrasonography and endorectal magnetic resonance imaging in the local staging of prostatic carcinoma. BJU Int 83: 796–800PubMedCrossRefGoogle Scholar
  37. Ellis WJ, Brawer NK (1993) PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia. Urol Clin North Am 20: 621–625PubMedGoogle Scholar
  38. Ellis WK, Brawer NK (1994) The significance of isoechoic prostatic carcinoma. J Urol 152: 2304–2307PubMedGoogle Scholar
  39. Farsad M, Schiavina R, Castellucci P et al. (2005) Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46: 1642–1649PubMedGoogle Scholar
  40. Fischer K, Loertzer H, Fornara P (2005) The use of complexed PSA for the early detection of prostate cancer. Anticancer Res 25: 1591–1596PubMedGoogle Scholar
  41. Fleshner N, Klotz L (2002) Role of “saturation biopsy” in the detection of prostate cancer among difficult diagnostic cases. Urology 60: 93–97PubMedCrossRefGoogle Scholar
  42. Fleshner NE, O’Sullivan M, Premdass C et al. (1999) Clinical significance of small (less than 0.2 cm3) hypoechoic lesions in men with normal digital rectal examinations and prostate-specific antigen levels less than 10 ng/mL. Urology 53: 356–358PubMedCrossRefGoogle Scholar
  43. Fornara P, Fabricius PG (1990) Diagnostische Wertigkeit des prostataspezifischen Antigens beim Prostatakarzinom. In: Staehler G, Fabricius PG (Hrsg) Prostatakarzinom. Springer Berlin Heidelberg New York, S 21–27Google Scholar
  44. Fornara P, Semjonow A (Hrsg) (2002) PSA: Der Weg zum Befund — Präanalytik und Analytik des prostataspezifischen Antigen. Zuckschwerdt, MünchenGoogle Scholar
  45. Garra BS (2007) Imaging and estimation of tissue elasticity by ultrasound. Ultrasound Q 23(4): 255–268PubMedCrossRefGoogle Scholar
  46. Gore JL, Shariat SF, Miles BJ (2001) Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 165: 1554–9PubMedCrossRefGoogle Scholar
  47. Haese A, de la Taille A, van Poppel H et al. (2008) Clinical utility of the PCA3 urine essay in European men scheduled for repeat biopsy. Eur Urol 54(5): 1081–88PubMedCrossRefGoogle Scholar
  48. Halpern EJ, Ramey JR, Strup SE et al. (2005) Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer 104: 2373–2383PubMedCrossRefGoogle Scholar
  49. Hammerer P, Augustin H, Blonski J et al. (2004) Einfluss der transrektalen Endosonographie auf die klinische Stadieneinteilung des nicht palpablen Prostatakarzinoms Eine Kontroverse zum TNM-System. Urologe A 43: 307–12PubMedCrossRefGoogle Scholar
  50. Hammerer P, Luboldt HJ, Fichtner J et al. (2002) Abklärung suspekter Befunde durch Biopsie. Folgeuntersuchungen bei negativer Biopsie. In: Leitlinie PSA-Bestimmung in der Prostatakarzinomdiagnostik (Früherkennung des Prostatakarzinoms). Leitlinien der deutschen Urologen, AWMF-Leitlinien-Register Nr. 043/036, S 33–36Google Scholar
  51. Hara M, Koyanagi Y, Inoue T et al. (1971) Some physico-chemical characteristics of Gamma-seminoproteing, an antigenic component specific for human seminal plasma. Jpn J Legal Med 25: 322–324Google Scholar
  52. Haukaas S, Roervik J, Halvorsen OJ et al. (1997) When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br J Urol 79: 770–776PubMedGoogle Scholar
  53. Hodge KK, McNeal JE, Stamey TA (1989) Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 142: 66–70PubMedGoogle Scholar
  54. Hubert RS, Vivanco I, Chen E et al. (1999) STEAP: a prostate-specific cellsurface antigen highly epressed in human prostate tumors. Proc Natl Acad Sci USA 96: 14523–8PubMedCrossRefGoogle Scholar
  55. Jung K, Meyer A, Lein M et al. (1998) Ratio of free-to-total prostate specific antigen in Serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J Urol 159: 1595–1598PubMedCrossRefGoogle Scholar
  56. Kanda T, Nakagomi K, Goto S, Torizuka T (2008) Visualization of prostate cancer with 11C-choline positron emission tomography (PET): localization of primary and recurrent prostate cancer. Hinyokika Kiyo. May; 54(5): 325–32Google Scholar
  57. Kashimoda S et al. (1990) Extraprostatic localization of prostate acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum. Pathol 21: 1108–1111CrossRefGoogle Scholar
  58. Kawakami S, Hyochi N, Yonese J et al. (2006) Three-dimensional combination of transrectal and transperineal biopsies for efficient detection of stage T1c prostate cancer. Int J Clin Oncol 11: 127–132PubMedCrossRefGoogle Scholar
  59. Keetch DW, Catalona WJ, Smith DS (1994) Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151: 1571–4PubMedGoogle Scholar
  60. Kojima Y, Nonomura N, Nose T et al. (2000) Transition zone biopsy in the detection of prostate cancer. Eur Urol 37: 675–679PubMedCrossRefGoogle Scholar
  61. Kumar A, Mikolajczyk SD, Goel AS et al. (1997) Expression of pro form of prostate-specific antigen by mammalian cells and its conversi on to mature, active form by human kallikrein 2. Cancer Res 57: 3111–3114PubMedGoogle Scholar
  62. Lee E, Torp-Pederson ST, Littrup PJ et al. (1989) Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination and prostate specific antigen. Radiology 170: 29–32PubMedGoogle Scholar
  63. Lein M, Jung K, Elgeti Uet al. (2000) Ratio of alpha 1-antichymotrypsin-prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis. Anticancer Res 20: 4997–5001PubMedGoogle Scholar
  64. Lein M (2002) Freies PSA — patientenabhängige Einflussgrößen. In: Fornara P, Semjonow A (Hrsg) PSA: Der Weg zum Befund — Präanalytik und Analytik des prostataspezifischen Antigens. Zuckschwerdt, München, S 16–22Google Scholar
  65. Levesque MA, Hu H, Costa MD et al. (1995) Prostate specific antigen expression by various tumors. Clin Lab Anal 9: 123–128CrossRefGoogle Scholar
  66. Lilja H, Oldbring J, Rannewik G et al. (1987) Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 80: 281–285PubMedCrossRefGoogle Scholar
  67. Littrup PJ (2001) Imaging and prostate cancer chemoprevention: Current diagnosis and future directions. Urology 57 (4 Suppl 1): 121–3PubMedCrossRefGoogle Scholar
  68. Loch T (2004) Computergestützter transrektaler Ultraschall (C-TRUS) in der Diagnostik des Prostatakarzinoms. Urologe A 43: 1377–84PubMedCrossRefGoogle Scholar
  69. Loch T, Leuschner I, Genberg C et al. (2000) Improvement of transrectal ultrasound. Artificial neural network analysis (ANNA) in detection and staging of prostatic carcinoma. Urologe A 39: 341–7PubMedCrossRefGoogle Scholar
  70. Loeb S, Roehl KA, Antenor JAV et al. (2006) Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67: 316–320PubMedCrossRefGoogle Scholar
  71. Loeb S, Roehl KA, Catalona WJ, Nadler RB (2007) Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 177(3): 899–902PubMedCrossRefGoogle Scholar
  72. Loertzer H, Fischer K, Fornara P (2005) PSA quick test in capillary blood. Anticancer Res 25: 1659–62PubMedGoogle Scholar
  73. Luboldt HJ, Doehn C (2002) Aufbereitung, Transport und Lagerung der Probe. In: Fornara P, Semjonow A (Hrsg) PSA: Der Weg zum Befund — Präanalytik und Analytik des Prostate-spezifischen Antigens. Zuckschwerdt, München, S 28–32Google Scholar
  74. Marks LS, Botswick DG (2008) Prostate cancer specificity of PCA3 gene testing: examples from clinical practice. Rev Urol 10(3): 175–81PubMedGoogle Scholar
  75. Mikolajczyk SD (2004) Serum pro-prostate specific antigen preferentially detects aggressive prostate Cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171: 2239–44PubMedCrossRefGoogle Scholar
  76. Mistry SJ, Bank A, Atweh GF (2005) Targeting stathmin in prostate cancer. Mol Cancer Ther 4: 1821–9PubMedCrossRefGoogle Scholar
  77. Nadler RB et al. (2005) Use of 2,6 ng/ml postate specific antigen prompt for biopsy in men older than 60 years. J Urol 174: 215–217CrossRefGoogle Scholar
  78. Nakanishi H et al. (2008) PCA-3 molecular urine assay correlates with prostate cancer tumour volume: implication in selecting candidates for active surveillance. J Urol 179:804–9CrossRefGoogle Scholar
  79. Nakanishi H, Groskopf J, Fritsche HA et al. (2008) PCA3 molecular urine essay correlates with prostate cancer tumour volume: implication in selecting candidates for active surveillance. J Urol 179(5): 1804–09PubMedCrossRefGoogle Scholar
  80. Norberg M, Egevad L, Holmberg L (1997). The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50: 562–6PubMedCrossRefGoogle Scholar
  81. Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907–923PubMedGoogle Scholar
  82. Oesterling JE, Rice RC, Genski WJ et al. (1994) Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. In: Murphy G, Khoury S, Chatelain C, Denis L (eds) Proceedings of the 4th International Symposium on recent advances in urologcal cancer. Scientific Communication International, Jersey, pp 99–109Google Scholar
  83. Oesterling JE, Kumamoto Y, Tsukamoto T et al. (1995) Serum prostate-specific antigen in a community-based population of healthy Japanese men: Iower values than for similarly aged white man. BJU 75: 347–353PubMedCrossRefGoogle Scholar
  84. Onder AU, Yalcin V, Arar O et al. (1998) Impact of transition zone biopsies in detection and evaluation of prostate cancer. Eur Urol 33: 542–8PubMedCrossRefGoogle Scholar
  85. Ornstein DK, Rao GS, Smith DS et al. (1997) Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J Urol 157: 195–198PubMedCrossRefGoogle Scholar
  86. Partin AW, Carter HB, Chan DE et al. (1990) Prostate specific antigen in the staging of localzed prostate cancer influence of tumor differentiation, tumor volume and benign prostatic hyperplasia. J Urol 143: 474–752Google Scholar
  87. Pepe P, Patane D, Panella P et al. (2003) Does the adjunct of ecographic contrast medium Levovist improve the detection rate of prostate cancer? Prostate Cancer Prostatic Dis 6: 159–62PubMedCrossRefGoogle Scholar
  88. Perrin P (2006) PSA Velocity and Prostate Cancer Detection: The absence of evidence is not the evidence of absence. Eur Urol 49: 418–419PubMedCrossRefGoogle Scholar
  89. Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J Urol 162: 293–306PubMedCrossRefGoogle Scholar
  90. Porkka KP, Helenius MA, Visakorpi T (2002) Cloning and characterization of a novel six-trans-membrane protein STEAP2, expressed in normal and malignant prostate. Lab Invest 82: 1573–82PubMedCrossRefGoogle Scholar
  91. Price CP, Allard J, Davies G et al. (2001) Pre-and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 38: 188–216PubMedCrossRefGoogle Scholar
  92. Remzi M, Djavan B, Wammack R et al. (2003) Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? Urology 61: 161–6PubMedCrossRefGoogle Scholar
  93. Rifkin MD, Zerhoni EA, Gatsornis CA et al. (1990) Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. N Engl J Med 323: 621–626PubMedCrossRefGoogle Scholar
  94. Roddam AW, Duffy MJ, Hamdy FC et al. (2005) On-behalf-of-the-NHS-Prostate-Cancer-risk-Management-Programme: Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systemataic review and metaanalysis. Eur Urol 48 386–99; discussion 398–9PubMedCrossRefGoogle Scholar
  95. Roehrborn CG, Pickens GJ, Sanders JS (1996) Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology 47: 347–52PubMedCrossRefGoogle Scholar
  96. Rozhansky F, Chen MH, Cox MC et al. (2006) Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 106 (1): 63–7PubMedCrossRefGoogle Scholar
  97. Ryan CJ, Small EJ (2006) Prostate cancer update: 2005. Curr Opin Oncol 18: 284–288PubMedGoogle Scholar
  98. Salomon G, Köllerman J, Thederan I et al. (2008) Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy. Eur Urol 54(6): 1354–62PubMedCrossRefGoogle Scholar
  99. Schellhammer PF, Wright GL (1993) Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Urol Clin Am 20: 597–606Google Scholar
  100. Schiavina R, Scattoni V, Castellucci P et al. (2008) (11)C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54(2): 392–401PubMedCrossRefGoogle Scholar
  101. Schilling D, Schlemmer HP, Wagner PH et al. (2008) Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 102(4): 446–51PubMedCrossRefGoogle Scholar
  102. Schmid HP, McNeal JE, Stamey TA (1993) Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71: 2031–2040PubMedCrossRefGoogle Scholar
  103. Schröder FH et al. (2006) Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 49: 460–5PubMedCrossRefGoogle Scholar
  104. Semjonow, A, Oberpenning F, Weining C et al. (2002) Unterschiede zwischen PSA-Bestimmungsverfahren. In Fornara P, Semjonow A (Hrsg): PSA: Der Weg zum Befund — Präanalytik und Analytik des prostataspezifischen Antigens. Zuckschwerdt, MünchenGoogle Scholar
  105. Smith JA, Middleton RG (1987) Methods of definitive local therapy. In: Smith JA, Middleton RG (eds) Clinical management of prostatic cancer. Year Book Medical, Chicago, pp 54–84Google Scholar
  106. Souchon R, Rouvière O, Gelet A et al. (2003) Visualisation of HIFU lesions using elastography of the human prostate in vivo: preliminary results. Ultrasound Med Biol 29(7): 1007–15PubMedCrossRefGoogle Scholar
  107. Stenman UH, Leinonen J, Alfthan H et al. (1991) A complex between prostate-specific antigen and alpha1-antichymotrypsin is the major from prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222–226PubMedGoogle Scholar
  108. Stephan C, Lein M, Jung K et al. (1997) The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 79: 104–9PubMedCrossRefGoogle Scholar
  109. Stephan C, Schnorr D, Loening SA et al. (2005) Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2–10 ng/ml: Systematic Review and Meta-Analysis. Eur Urol 48: 386–99CrossRefGoogle Scholar
  110. Strohmaier WL (2002) Gesamt-PSA — patientenabhängige Einflußgrößen. In: Fornara P, Semjonow A (Hrsg) PSA: Der Weg zum Befund — Präanalytik und Analytik des prostataspezifischen Antigens. Zuckschwerdt, München, S 1–15Google Scholar
  111. Tarcan T, Ozveri H, Biren T (1997) Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels. Int J Urol 4 (4): 362–7PubMedCrossRefGoogle Scholar
  112. Trabulsi EJ, Merriam WG, Gomella LG (2006) New imaging techniques in prostate cancer. Curr Urol Rep 7: 175–80PubMedCrossRefGoogle Scholar
  113. UICC (2002) TNM-Klassifikation maligner Tumoren, 6. Aufl. Springer, Berlin Heidelberg New York, S 162–165Google Scholar
  114. Yang D, Holt GE, Velders MP et al. (2001) Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 61: 5857–60PubMedGoogle Scholar
  115. Yu H, Diamandis EP (1995) Measurement of prostate specific antigen level in the serum of females and prostatectomized males with an ultrasensitive immunoassay technique. J Urol 153: 1004PubMedCrossRefGoogle Scholar
  116. Yu H, Diamandis EP, Sutherland DJA (1994) Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 27: 75–78PubMedCrossRefGoogle Scholar

Literatur zu Kap. 25.5

  1. Ahmed S, Lindsey B, Davies J: Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy. Prostate Cancer Prostatic Dis 2005;8: 31–35PubMedCrossRefGoogle Scholar
  2. Ahmed HU, Ishaq A, Zacharakis E, Shaw G, Illing R, Allen C, Kirkham A, Emberton M: Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachy-therapy and external beam radiotherapy. BJU Int 2008 [Epub ahead of print]Google Scholar
  3. Albertsen PC, Hanley JA, Gleason DF, Barry MJ: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998, 280: 975–980PubMedCrossRefGoogle Scholar
  4. Allaf M E, Carter HB: Update on watchful waiting for prostate cancer. Curr Opin Urol 2004;14: 171–174PubMedCrossRefGoogle Scholar
  5. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37: 1035–1041Google Scholar
  6. Amling CL, Bergstralh EJ, Blute ML, Slezak JM; Zincke H.: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001;165: 1146–1151PubMedCrossRefGoogle Scholar
  7. Anderson JK, Murdock A, Cadeddu JA, Lotan Y: Cost comparison of laparoscopic versus radical retropublic prostatectomy. Urology 2005;66: 557–560PubMedCrossRefGoogle Scholar
  8. Ataman F, Zurlo A, Artignan X, van Tienhoven G, Blank LE, Warde P, Dubois JB, Jeanneret W, Keuppens F, Bernier J, Kuten A, Collette L, Pierart M, Bolla M: Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer 2004;40: 1674–1681PubMedCrossRefGoogle Scholar
  9. Augustin H, Hammerer P, Graefen M, Palisaar J, Noldus J, Fernandez S, Huland H: Intraoperative and perioperative morbidity of contemporary radical retropublic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur Urol 2003;43: 113–118PubMedCrossRefGoogle Scholar
  10. Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K: Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year followup of a randomized controlled trial. BJU Int 2002;90: 561–566PubMedCrossRefGoogle Scholar
  11. Badani KK, Kaul S, Menon M: Evolution of robotic radical prostatectomy: assessment after 2766 procedures. Cancer. 2007;110: 1951–1958PubMedCrossRefGoogle Scholar
  12. Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, Gleason DF, Zincke H, Bergstralh EJ, Jacobsen SJ. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001;91: 2302–2314PubMedCrossRefGoogle Scholar
  13. Basillote JB, Ahlering TE, Skarecky DW, Lee DI, Clayman RV: Laparoscopic radical prostatectomy. Review and assessment of an emerging technique. Surg Endosc 2004;18: 1694–1711PubMedCrossRefGoogle Scholar
  14. Baumert H, Fromont G, Adorno Rosa J, Cahill D, Cathelineau X, Vallancien G: Impact of learning curve in laparoscopic radical prostatectomy on margin status: prospective study of first 100 procedures performed by one surgeon. J Endourol 2004;18: 173–176PubMedCrossRefGoogle Scholar
  15. Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA: Increased risk of rectal cancer after prostate radiation: A populationbased study. Gastroenterology 2005;128: 819–824PubMedCrossRefGoogle Scholar
  16. Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren, JL, Scardino PT: Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346: 1138–1144PubMedCrossRefGoogle Scholar
  17. Beyer DC, McKeough T, Thomas T: Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;61: 1299–1305PubMedGoogle Scholar
  18. Bhandari A, McIntire L, Kaul SA, Hemal AK, Peabody JO, Menon M: Perioperative complications of robotic radical prostatectomy after the learning curve. J Urol 2005;174: 915–918PubMedCrossRefGoogle Scholar
  19. Bianco FJ Jr, Wood DP Jr, Cher ML, Powell IJ, Souza JW, Pontes JE: Tenyear survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer 2003;1: 242–247PubMedGoogle Scholar
  20. Bianco FJ Jr, Scardino PT, Eastham JA: Radical prostatectomy: longterm cancer control and recovery of sexual and urinary function (“trifecta”). Urology 2005;66(5 Suppl): 83–94PubMedCrossRefGoogle Scholar
  21. Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE; Scandinavian Prostate Cancer Group Study Number 4: Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008 20;100: 1144–54Google Scholar
  22. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337: 295–300PubMedCrossRefGoogle Scholar
  23. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360: 103–106PubMedCrossRefGoogle Scholar
  24. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M, for the European Organization for Research and Treatment of Cancer: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366: 572–578PubMedCrossRefGoogle Scholar
  25. Bonkhoff H: Prognosefaktoren des Prostatakarzinoms. Pathologe 2005;26: 433–443PubMedCrossRefGoogle Scholar
  26. Brehmer B, Borchers H, Kirschner-Hermanns R, Biesterfeld S, Jakse G: Perioperative morbidity of the extended radical perineal prostatectomy. Eur Urol 2001;40: 139–143PubMedCrossRefGoogle Scholar
  27. Briganti A, Chun FK, Salonia A, Zanni G, Scattoni V, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI: Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 2006;49: 1019–1026PubMedCrossRefGoogle Scholar
  28. Briganti A, Karakiewicz PI, Joniau S, Van Poppel H. The Motion: Nomograms Should Become a Routine Tool in Determining Prostate Cancer Prognosis. Eur Urol 2008 [Epub ahead of print]Google Scholar
  29. Carini M, Masieri L, Minervini A, Lapini A, Serni S: Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer. Eur Urol 2008;53: 554–561PubMedCrossRefGoogle Scholar
  30. Carter CA, Donohue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackman S, Moul J: Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 2003;21: 4001–4008PubMedCrossRefGoogle Scholar
  31. Catalona WJ, Ramos GR, Carvalhal GF: Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 1999a;49: 282–296PubMedCrossRefGoogle Scholar
  32. Catalona WJ, Carvalhal GF, Mager DE, Smith DS: Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999b;162: 433–438PubMedCrossRefGoogle Scholar
  33. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40: 373–383PubMedCrossRefGoogle Scholar
  34. Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO: Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J Urol 2005;174: 2181–2185PubMedCrossRefGoogle Scholar
  35. Chun J, Pruthi RS: Is neoadjuvant hormonal therapy before radical prostatectomy indicated? Urol Int 2004;72: 275–80PubMedCrossRefGoogle Scholar
  36. Cohn JH, el-Galley R: Radical prostatectomy in a community practice. J Urol 2002;167: 224–228PubMedCrossRefGoogle Scholar
  37. Dahm P, Silverstein AD, Weizer AZ, Crisci A, Vieweg J, Paulson DF. When to diagnose and how to treat prostate cancer in the “not too fit” elderly. Crit Rev Oncol Hematol 2003;48: 123–131PubMedCrossRefGoogle Scholar
  38. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280: 969–974PubMedCrossRefGoogle Scholar
  39. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW: 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA. 2004a:292: 821–827PubMedCrossRefGoogle Scholar
  40. D’Amico AV, Chen MH, Roehl KA, Catalona WJ: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004b;351: 125–135PubMedCrossRefGoogle Scholar
  41. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299: 289–295PubMedCrossRefGoogle Scholar
  42. Deger S, Böhmer D, Roigas J, Türk I, Budach V, Loening S.A: Brachytherapie des lokalen Prostatakarzinoms. Urologe A 2001;40: 181–184PubMedCrossRefGoogle Scholar
  43. Dicker AP, Lin CC, Leeper DB, Waterman FM: Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 1251 based on radiobiological effectiveness and dosimetry. Semin Urol Oncol 2000;18: 152–159PubMedGoogle Scholar
  44. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ: Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95: 868–878PubMedCrossRefGoogle Scholar
  45. Eastham JA, Kattan MW, Rogers E, Goad JR, Ohori M, Boone TB, Scardino PT: Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996;156: 1707–1713PubMedCrossRefGoogle Scholar
  46. EUA-Guidelines 2008: Heidenreich A, Aus G, Abbou CC, Bolla M, Joniau S, Matveev V, Schmid HP, Zattoni F: Guidelines on prostate cancer. Website: http: //www.uroweb.org/fileadmin/tx_eauguidelines/ Prostate%20Cancer.pdf (zuletzt besucht: 31.12.2008)Google Scholar
  47. Eggener SE, Vickers AJ, Serio AM, Donovan MJ, Khan FM, Bayer-Zubek V, Verbel D, Cordon-Cardo C, Reuter VE, Bianco FJ Jr, Scardino PT: Comparison of models to predict clinical failure after radical prostatectomy. Cancer 2008 [Epub ahead.of print]Google Scholar
  48. Epstein JI, Partin AW, Sauvageot J, Walsh PC: Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20: 286–292PubMedCrossRefGoogle Scholar
  49. Fowler JE, Terrell FL, Renfroe DL: Co-Morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 1996;156: 1714–1718PubMedCrossRefGoogle Scholar
  50. Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ: Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol 2002;168: 110–115PubMedCrossRefGoogle Scholar
  51. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294: 433–439PubMedCrossRefGoogle Scholar
  52. Freedland SJ, Moul JW: Prostate specific antigen recurrence after definitive therapy. J Urol 2007;177: 1985–1991PubMedCrossRefGoogle Scholar
  53. Frohmüller HG, Theiss M, Manseck A, Wirth MP: Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur Urol 1995;27: 202–206PubMedGoogle Scholar
  54. Fröhner, M.: Die prognostische Bedeutung der Komorbidität bei der radikalen Prostatektomie. Habilitationsschrift, Technische Universität Dresden, 2007Google Scholar
  55. Froehner M: Life expectancy estimation by nomogram. J Clin Oncol 2008a;26: 690PubMedCrossRefGoogle Scholar
  56. Froehner M, Koch R, Litz RJ, Hakenberg OW, Oehlschlaeger S, Wirth MP. Interaction between age and comorbidity as predictors of mortality after radical prostatectomy. J Urol 2008b;179: 1823–1829PubMedCrossRefGoogle Scholar
  57. Froehner M, Koch R, Litz RJ, Hakenberg OW, Oehlschlaeger S, Wirth MP: Survival analysis in men undergoing radical prostatectomy at an age of 70 years of older. Urol Oncol 2009a (im Druck)Google Scholar
  58. Froehner M, Koch R, Litz RJ, Wirth MP: Nomogram underestimates 10-year survival in healthy men selected for radical prostatectomy at an age of 70 or more years. Urology 2009b (im Druck)Google Scholar
  59. Ganswindt U, Stenzl A, Bamberg M, Belka C: Adjuvant radiotherapy for patients with locally advanced prostate cancer—a new standard? Eur Urol 2008;54: 528–542PubMedCrossRefGoogle Scholar
  60. Geary ES, Dendinger TE, Freiha FS, Stamey TA: Incontinence and vesical neck strictures following radical retropubic prostatectomy. Urology 1995;45: 1000–1006PubMedCrossRefGoogle Scholar
  61. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H: Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999;161: 1223–1227PubMedCrossRefGoogle Scholar
  62. Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD: Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 2000;56: 289–294PubMedCrossRefGoogle Scholar
  63. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S; Canadian Uro-Oncology Group: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166: 500–506PubMedCrossRefGoogle Scholar
  64. Gleave M, Kelly WK: High-risk localized prostate cancer: a case for early chemotherapy. J Clin Oncol 2005;23: 8186–8191PubMedCrossRefGoogle Scholar
  65. Granfors T, Modig H, Damber JE, Tomic R: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998;159: 2030–2034PubMedCrossRefGoogle Scholar
  66. Gray M, Petroni GR, Theodorescu D: Urinary function after radical prostatectomy: a comparison of the retropublic and perineal approaches. Urology 1999;53: 881–890PubMedCrossRefGoogle Scholar
  67. Gretzer MB, Trock B, Han M, Walsh PC: A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol 2002;168: 1419–1422PubMedCrossRefGoogle Scholar
  68. Guillonneau B, Cathelineau X, Doublet JD, Baumert H, Vallancien G. Laparoscopic radical prostatectomy: assessment after 550 procedures. Crit Rev Oncol Hematol 2002;43: 123–133PubMedCrossRefGoogle Scholar
  69. Han M, Pound CR, Potter SR, Partin AW, Epstein JI, Walsh PC: Isolated local recurrence is rare after radical prostatectomy in men with Gleason score 7 prostate cancer and positive surgical margins: Therapeutic implications. J Urol 2001;165: 864–866PubMedCrossRefGoogle Scholar
  70. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169: 517–523PubMedCrossRefGoogle Scholar
  71. Hanks GE, Lu J, Machtay M, Venkatesan V, Pinover W, Byhardt R, Rosenthal SA: RTOG Protocol 92-02: A phase III trial of the use of longterm androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc ASCO 2000;19: 327a (abstract)Google Scholar
  72. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21: 3972–3978PubMedCrossRefGoogle Scholar
  73. Hayes SB, Pollack A: Parameters for treatment decisions for salvage radiation therapy. J Clin Oncol 2005;23: 8204–8211PubMedCrossRefGoogle Scholar
  74. Hersh MR, Knapp EL, Choi J: Newer imaging modalities to assess tumor in the prostate. Cancer Control 2004;11: 353–357PubMedGoogle Scholar
  75. Hoskin P: High dose rate brachytherapy for prostate cancer. CanceR Radiother 2008;12: 512–514PubMedGoogle Scholar
  76. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO: The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008;63: 387–395PubMedCrossRefGoogle Scholar
  77. Hricak H: New horizons in genitourinary oncologic imaging. Abdom Imaging 2006;31: 182–187PubMedCrossRefGoogle Scholar
  78. Hu JC, Wang Q, Pashos CL, Lipsitz SR, Keating NL: Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol 2008;26: 2278–2284PubMedCrossRefGoogle Scholar
  79. Huland H: Radical prostatectomy: options and issues. Eur Urol 2001;39 (suppl. 1): 3–9PubMedCrossRefGoogle Scholar
  80. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002;167: 528–534PubMedCrossRefGoogle Scholar
  81. Iselin CE, Robertson JE, Paulson DF: Radical perineal prostatectomy: oncological outcome during a 20-year. period. J Urol. 1999;161: 163–168PubMedCrossRefGoogle Scholar
  82. Jani AB, Hellmann S: Early prostate cancer: clinical decision making. Lancet 2003;361: 1045–1053PubMedCrossRefGoogle Scholar
  83. Jakse G, Manegold E, Reineke T, Borchers H, Brehmer B, Wolff JM, Mittermayer C: Die erweiterte, radikale perineale Prostatektomie. Urologe A 2000;39: 455–462PubMedCrossRefGoogle Scholar
  84. Jeschke S, Nambirajan T, Leeb K, Ziegerhofer J, Sega W, Janetschek G: Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2005;173: 1943–1946PubMedCrossRefGoogle Scholar
  85. Jhaveri FM, Zippe CD, Klein EA, Kupelian PA: Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 1999;54: 884–890PubMedCrossRefGoogle Scholar
  86. Johansson JE, Andren O, Andersson SO, Dickmann PW, Holmberg L, Magnuson A, Adami HO: Natural history of early, localized prostate cancer. JAMA 2004;291: 2713–2719PubMedCrossRefGoogle Scholar
  87. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17: 1499–1507PubMedGoogle Scholar
  88. Keller H, Schmeller N; Janetschek G: Urinary continence after retropubic perineal, and laparoscopic radical prostatectomy: prospective study. Eur Urol Suppl 2005;4, No. 3: 103CrossRefGoogle Scholar
  89. Khan MA, Partin AW: Management of high-risk populations with locally advanced prostate cancer. Oncologist 2003;8: 259–269PubMedCrossRefGoogle Scholar
  90. Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M: Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004;172: 508–511PubMedCrossRefGoogle Scholar
  91. Klotz LH, Goldenberg SL, Jewett MAS, Fradet Y, Nam R, Barkin J, Chin J, Chatterjee S; Canadian Uro-Oncology Group: Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003;170: 791–794PubMedCrossRefGoogle Scholar
  92. Klotz L: Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006;24: 46–50PubMedGoogle Scholar
  93. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, Schuster T, Geinitz H, Treiber U, Schwaiger M: The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35: 18–23PubMedCrossRefGoogle Scholar
  94. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ: Potency, continence and complication rates in 3.477 consecutive radical retropubic prostatectomies. J Urol 2004;172: 2227–2231PubMedCrossRefGoogle Scholar
  95. Kupelian P, Katcher J, Levin H, Zippe C, Klein E: Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996;48: 249–260PubMedCrossRefGoogle Scholar
  96. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H: Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 2002;167: 117–122PubMedCrossRefGoogle Scholar
  97. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV: Updated results of the phase III radiation therapy oncology group (RTOG) trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49: 937–946PubMedCrossRefGoogle Scholar
  98. Leandri P, Rossignol G, Gautier JR, Ramon J: Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol 1992;147: 883–887PubMedGoogle Scholar
  99. Lee F, Siders DB, McHugh TA, Solomon MH, Mayman DM: Neoadjuvant androgen ablation therapy prior to radical prostatectomy: Results of a 3-year follow-up. Endocr Relat Cancer 1996;3: 171–177CrossRefGoogle Scholar
  100. Lepor H: Selecting candidates for radical prostatectomy. Rev Urol 2000;2: 182–189PubMedGoogle Scholar
  101. Lepor H, Nieder AM, Fernandino MN: Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1000 cases. J Urol 2001;166: 1729–1733PubMedCrossRefGoogle Scholar
  102. Lepor H: Radical prostatectomy: status and opportunities for improving outcomes. Cancer Invest 2004;22: 435–444PubMedCrossRefGoogle Scholar
  103. Loeb S, Roehl KA, Helfand BT, Catalona WJ: Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Urology 2008;72: 887–891PubMedCrossRefGoogle Scholar
  104. Lohr F, Boda-Heggemann J, Wenz F, Wiegel T: Bildgesteuerte Strahlentherapie des Prostatakarzinoms. Aktuelle Urol 2007;38: 386–391PubMedCrossRefGoogle Scholar
  105. Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R: Current practice of Gleason grading of prostate carcinoma Virchows Arch 2006;448: 111–118PubMedCrossRefGoogle Scholar
  106. Malmström PU: Lymph node staging in prostatic carcinoma revisited. Acta Oncol 2005;44: 593–598PubMedCrossRefGoogle Scholar
  107. Martinez de la Riva SI, Lopez-Tomasety JB, Marrero Dominguez R, Santamaria Blanco P: Perineal radical prostatectomy as monotherapy: ten-year experience. (Article in Spanish) Arch Esp Urol 2004;57: 397–411PubMedGoogle Scholar
  108. Martis G, Diana M, Ombres M, Cardi A, Mastrangeli R, Mastrangeli B: Retropubic versus perineal radical prostatectomy in early prostate cancer: eight-year experience. J Surg Oncol 2007;95: 513–518PubMedCrossRefGoogle Scholar
  109. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; the Casodex Early Prostate Cancer Trialists Group: Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97: 247–254PubMedCrossRefGoogle Scholar
  110. Menon M, Shrivastava A, Sarle R, Hemal A, Tewari A: Vattikuti Institute Prostatectomy: a single-team experience of 100 cases. J Endourol 2003;17: 785–790PubMedCrossRefGoogle Scholar
  111. Menon M, Shrivastava A, Tewari A: Laparocopic radical prostatectomy: conventional and laparoscopic. Urology 2005;66(Suppl 5A): 101–104PubMedCrossRefGoogle Scholar
  112. Menon M, Shrivastava A, Kaul S, Badani KK, Fumo M, Bhandari M, Peabody JO: Vattikuti Institute prostatectomy: contemporary technique and analysis of results. Eur Urol 2007;51: 648–657PubMedCrossRefGoogle Scholar
  113. Meraney AM, Haese A, Palisaar J, Graefen M, Steuber T, Huland H, Klein EA: Surgical management of prostate cancer: advances based on a rational approach to the data. Eur J Cancer 2005;41: 888–907PubMedCrossRefGoogle Scholar
  114. Merrick GS, Wallner KE, Butler WM: Prostate cryotherapy: more questions than answers. Urology 2005;66: 9–15PubMedCrossRefGoogle Scholar
  115. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Engl J Med 1999;341: 1781–1788PubMedCrossRefGoogle Scholar
  116. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di’SantAgnese PA, Trump D; Eastern Cooperative Oncology Group study EST 3886: Immediate versus defferred androgen deprivation treatment in patients with node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7: 472–47PubMedCrossRefGoogle Scholar
  117. Morton GC: The emerging role of high-dose-rate brachytherapy for prostate cancer. Clinical Oncology 2005;17: 219–227PubMedCrossRefGoogle Scholar
  118. Mottrie A, Van Migem P, De Naeyer G, Schatteman P, Carpentier P, Fonteyne E: Robot-assisted laparoscopic radical prostatectomy: oncologic and functional results of 184 cases. Eur Urol 2007;52: 746–750PubMedCrossRefGoogle Scholar
  119. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O’Reilly K, Hernandez J, Chung A, Soderdahl D: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004;171: 1141–1147PubMedCrossRefGoogle Scholar
  120. Nguyen PL, Trofimov A, Zietman AL: Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer? Oncology (Williston Park) 2008;22: 748–754Google Scholar
  121. Nguyen PL, Chen MH, Catalona WJ, Alexander BM, Roehl KA, Loeb S, D’Amico AV: Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer: implications for management. Cancer 2008;113: 3146–3152PubMedCrossRefGoogle Scholar
  122. Noldus J, Huland H: Die operative Therapie des Prostatakarzinoms. Onkologie 2003;26: 6–12PubMedCrossRefGoogle Scholar
  123. Oefelein MG, Smith ND, Grayhack JT, Schaeffer AJ, McVary KT: Longterm results of radical retropublic prostatectomy in men with high grade carcinoma of the prostate. J Urol 1997;158: 1460–1465PubMedCrossRefGoogle Scholar
  124. Oh WK: Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urol Oncol 2003;21: 229–234PubMedGoogle Scholar
  125. Oh RJ, Yoshioka Y, Tanaka E, Shiomi H, Sumida I, Isohashi F, Suzuki O, Konishi K, Kawaguchi Y, Nakamura S, Kato M, Inoue T: High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: results of a retrospective analysis. Radiat Med 2006;24: 58–64PubMedCrossRefGoogle Scholar
  126. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer. J Urol 1994;152: 1843–1849PubMedGoogle Scholar
  127. Olsson LE, Salomon L, Nadu A, Hoznek A, Cicco A, Saint F, Chopin D, Abbou CC: Prospective patient-reported continence after laparoscopic radical prostatectomy. Urology 2001;58: 570–572PubMedCrossRefGoogle Scholar
  128. Ornstein DK, Oh J, Herschman JD, Andriole GL: Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am 1998;23: 591–601CrossRefGoogle Scholar
  129. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathologic stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277: 1445–1451PubMedCrossRefGoogle Scholar
  130. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millenium. Urology 2001;58: 843–848PubMedCrossRefGoogle Scholar
  131. Peschel RE, Colberg JM: Surgery, brachytherapy, and external beam radiotherapy for early prostate cancer. Lancet Oncology 2003;4: 233–241PubMedCrossRefGoogle Scholar
  132. Pettus JA, Weight CJ, Thompson CJ, Middleton RG, Stephenson RA: Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol 2004;172: 129–132PubMedCrossRefGoogle Scholar
  133. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D: Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50: 1243–1252PubMedGoogle Scholar
  134. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I: Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000;18: 3904–3911PubMedGoogle Scholar
  135. Porter CR, Gallina A, Kodama K, Gibbons RP, Correa R Jr, Perrotte P, Karakiewicz PI: Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy. Eur Urol 2007;52:446–452PubMedCrossRefGoogle Scholar
  136. Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, Mullen E: 12-year outcomes following permanent prostate brachy-therapy in patients with clinically localized prostate cancer. J Urol 2005;173: 1562–1566PubMedCrossRefGoogle Scholar
  137. Pound CR, Partin AW, Epstein JI, Walsh PC: Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am 1997;24: 395–406PubMedCrossRefGoogle Scholar
  138. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281: 1591–1597PubMedCrossRefGoogle Scholar
  139. Prayer-Galetti T, Zattoni F, Capizzi A, Dal Moro F, Pagano F on behalf on the study group: Disease free survival in patients with pathological “C stage” prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment. Eur Urol 2000;38(Suppl 4): 504 (abstract)Google Scholar
  140. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D: Phase III trial of androgen suppression using goserelin in unfavourable prognosis carcinoma of the prostate treated with definitive radiotherapy — report of RTOG protocol 85–31. J Clin Oncol 1997;15: 1013–1021PubMedGoogle Scholar
  141. Pilepich MV, Winter K, Lawton C, Krisch RE, Wolkov H, Movsas B, Hug E, Asbell S, Grignon D: Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. Long-term results of phase III RTOG trial 85–31. Int J Radiat Oncol Biol Phys 2003;57(suppl. 2): S172–S173 (abstract)Google Scholar
  142. Quinlan DM, Epstein JI, Carter BS, Walsh PC: Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 1991;145: 998–1002PubMedGoogle Scholar
  143. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT: Factors predicting recovery of erections after radical prostatectomy. J Urol 2000;164: 1929–34PubMedCrossRefGoogle Scholar
  144. Rassweiler J, Seemann O, Schulze M, Teber D, Hatzinger M, Frede T: Laparoscopic versus open radical prostatectomy: a comparative study at a single institution. J Urol 2003;169: 1689–1693PubMedCrossRefGoogle Scholar
  145. Rassweiler J, Stolzenburg J, Sulser T, Deger S, Zumbe J, Hofmockel G, John H, Janetschek G, Fehr JL, Hatzinger M, Probst M, Rothenberger KH, Poulakis V, Truss M, Popken G, Westphal J, Alles U, Fornara P: Laparoscopic radical prostatectomy — the experience of the German laparoscopic working group. Eur Urol 2006;49: 113–119PubMedCrossRefGoogle Scholar
  146. Rebillard X, Soulié M, Chartier-Kastler E, Davin JL, Mignard JP, Moreau JL, Coulange C; Association Francaise d’Urologie: High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int. 2008;101: 1205–1213PubMedCrossRefGoogle Scholar
  147. Rodriguez E Jr, Finley DS, Skarecky D, Ahlering TE: Single institution 2-year patient reported validated sexual function outcomes after nerve sparing robot assisted radical prostatectomy. J Urol 2009;181: 259–263PubMedCrossRefGoogle Scholar
  148. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172: 910–914PubMedCrossRefGoogle Scholar
  149. Rosenthal SA, Bae K, Pienta KJ, Sobczak ML, Asbell SO, Rajan R, Kerlin KJ, Michalski JM, Sandler HM: Phase III multiinstitutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long term androgen suppression therapy and radiotherapy versus long term androgen suppression plus radiotherapy alone for high risk prostate cancer: preliminary toxicity analysis of RTOG 99. Int J Radiat Oncol Biol Phys 2008 [Epub ahead of print]Google Scholar
  150. Routh JC, Leibovich BC: Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc 2005;80: 899–907PubMedCrossRefGoogle Scholar
  151. Salomon L, Levrel O, Anastasiadis AG, Irani J, De La Taille A, Saint F, Vordos D, Cicco A, Hoznek A, Chopin D, Abbou CC: Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 2003;43: 39–44PubMedCrossRefGoogle Scholar
  152. Sandler HM, Eisenberger MA: Assessing und treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol 2007;178: S20–24CrossRefGoogle Scholar
  153. Schilling D, Schlemmer HP, Wagner PH, Böttcher P, Merseburger AS, Aschoff P, Bares R, Pfannenberg C, Ganswindt U, Corvin S, Stenzl A: Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008;102: 446–451PubMedCrossRefGoogle Scholar
  154. Schroeck FR, Krupski TL, Sun L, Albala DM, Price MM, Polascik TJ, Robertson CN, Tewari AK, Moul JW: Satisfaction and regret after open retropubic or robot assisted laparoscopic radical prostatectomy. Eur Urol 2008;54: 785–793.PubMedCrossRefGoogle Scholar
  155. Schumacher M, Burkhard FC, Studer UE: Stellenwert der pelvinen Lymphadenektomie beim klinisch lokalisierten Prostatakarzinom. Urologe (A) 2005;44: 645–651CrossRefGoogle Scholar
  156. Secin FP, Karanikolas N, Kuroiwa K, Vickers A, Touijer K, Guillonneau B: Positive surgical margins and accessory pudendal artery preservation during laparoscopic radical prostatectomy. Eur Urol 2005;48: 786–792. Shariat SF, Karakiewicz PI, Suardi N, Kattan MW, Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 2008;14: 4400–4407PubMedCrossRefGoogle Scholar
  157. Shelley M, Wilt TJ, Coles B, Mason MD: Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev. 2007;(3): CD005010PubMedGoogle Scholar
  158. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD: A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2008 [Epub ahead of print]Google Scholar
  159. Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Myers RP, Zincke H, Blute ML: Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol 2006;175: 952–957PubMedCrossRefGoogle Scholar
  160. Scardino PT: The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc 2000;111: 201–241PubMedGoogle Scholar
  161. Scolieri MJ, Altman A, Resnick ML: Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000;164: 1465–1472PubMedCrossRefGoogle Scholar
  162. Scott WW: An evaluation of endocrine therapy plus radical prostatectomy in the treatment of advanced carcinoma of the prostate. J Urol 1964;91: 97–102PubMedGoogle Scholar
  163. See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T: Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly increases the risk of PSA progression in early prostate cancer. Eur Urol 2003;44: 512–517PubMedCrossRefGoogle Scholar
  164. Stattaus J, Forsting M: Bedeutung der radiologischen Bildgebung für die Lymphknotenchirurgie urologischer Malignome. Urologe 2008 [Epub ahead of print]Google Scholar
  165. Steiner MS, Morton RA, Walsh PC: Impact of anatomical radical prostatectomy on urinary continence. J Urol 1991;145: 512–514PubMedGoogle Scholar
  166. Stephenson AJ, Scardino PT, Bianco FJ Jr, DiBlasio CJ, Fearn PA, Eastham JA: Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004;172: 2239–2243PubMedCrossRefGoogle Scholar
  167. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW: Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23: 7005–7012PubMedCrossRefGoogle Scholar
  168. Stephenson AJ, Eastham JA: Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005;23: 8198–8203PubMedCrossRefGoogle Scholar
  169. Stolzenburg JU, Rabenalt R, Do M, Kallidonis P, Liatsikos EN: Endoscopic extraperitoneal radical prostatectomy: the University of Leipzig experience of 2000 cases. J Endourol 2008;22: 2319–2325PubMedCrossRefGoogle Scholar
  170. Stübinger SH, Wilhelm R, Kaufmann S, Döring M, Hautmann S, Jünemann KP, Galalae R: Brachytherapie des Prostatakarzinoms. Urologe A 2008;47: 284–290PubMedCrossRefGoogle Scholar
  171. Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, Knönagel H, Loidl W, Isorna S, Sundaram SK, Debois M; EORTC Genitourinary Group: Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53: 941–949PubMedCrossRefGoogle Scholar
  172. Stuschke M, Budach V, Böhmer D: Strahlentherapie des Prostatakarzinoms. Deutsches Ärzteblatt 2004;101: 2690–2694Google Scholar
  173. Sullivan LD, Weir MJ, Kinahan JF, Taylor DL: A comparison of the relative merits of radical perineal and radical retropubic prostatectomy. BJU Int 2000;85: 95–100PubMedCrossRefGoogle Scholar
  174. Sofer M, Hamilton-Nelson KL, Schlesselman JJ, Soloway MS: Risk of positive margins and biochemical recurrence in relation to nervesparing radical prostatectomy. J Clin Oncol 2002;20: 1853–1858PubMedCrossRefGoogle Scholar
  175. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A: The Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167: 112–116PubMedCrossRefGoogle Scholar
  176. Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H: Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 2002;168: 525–529PubMedCrossRefGoogle Scholar
  177. Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, Slawin K, Scardino PT: Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005;174: 903–907PubMedCrossRefGoogle Scholar
  178. Tewari A, Hasan M, Devine G, Menon M: What actually determines the mortality in men with prostate cancer. J Urol 2004;171 suppl; 124 (abstract)Google Scholar
  179. Tewari A, El-Hakim A, Leung RA: Robotic prostatectomy: a pooled analysis of published literature. Expert Rev Anticancer Ther 2006 Jan; 6: 11–20PubMedCrossRefGoogle Scholar
  180. Theil R: Die radikale retropubische Prostatektomie — Goldstandard beim Prostatakarzinom? Urologe A 2004;43: 38–42CrossRefGoogle Scholar
  181. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED: Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296: 2329–2335PubMedCrossRefGoogle Scholar
  182. Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML: Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol 2006;175: 547–551PubMedCrossRefGoogle Scholar
  183. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE: Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 2005;65: 178–187PubMedCrossRefGoogle Scholar
  184. Touijer K, Eastham JA, Secin FP, Romero Otero J, Serio A, Stasi J, Sanchez-Salas R, Vickers A, Reuter VE, Scardino PT, Guillonneau B: Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J Urol 2008;179: 1811–1817PubMedCrossRefGoogle Scholar
  185. Trabulsi EJ, Guillonneau B: Laparoscopic radical prostatectomy. J Urol 2005;173: 1072–1079. Trapasso JG, DeKernion JB, Smith RB, Dorey F: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152: 1821–1825PubMedCrossRefGoogle Scholar
  186. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299: 2760–2769PubMedCrossRefGoogle Scholar
  187. Türk I, Deger IS, Winkelmann B, Roigas J, Schönberger B, Loening SA: Die laparoskopische radikale Prostatektomie. Erfahrungen mit 145 Eingriffen. Urologe A 2001;40: 199–206PubMedCrossRefGoogle Scholar
  188. Twelker L, Hakenberg O, Fröhner M, Oehlschläger S, Leike S, Manseck A, Wirth M: Positive Resektionsränder nach retropubischer radikaler Prostatektomie — Häufigkeiten und Lokalisation. Urologe A 2006;45 (Suppl. 1): S71 (Abstract)Google Scholar
  189. Twelker L, Fröhner M, Oehlschläger S, Leike S, Wirth M: Komplikationen bei retropubischer radikaler Prostatektomie bei Patienten über 70 Jahre. Urologe A 2007;46 (Suppl. 1): S42 (Abstract)Google Scholar
  190. Tyrrell CJ: Adjuvant and neoadjuvant hormonal therapy for prostate cancer. Eur Urol 1999;36: 549–558PubMedCrossRefGoogle Scholar
  191. Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C; ‘Casodex’ Early Prostate Cancer Trialists Group: Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol. 2005;76: 4–10PubMedCrossRefGoogle Scholar
  192. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH: Outcomes of Men with screen detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2008 [Epub ahead of print]Google Scholar
  193. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, Bosset JF, Kurth KH, Schröder FH, Collette L; EORTC 22911: Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007;25: 4178–86PubMedCrossRefGoogle Scholar
  194. Vickers AJ, Bianco FJ, Gonen M, Cronin AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT: Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol 2008;53: 960–966PubMedCrossRefGoogle Scholar
  195. Walsh PC, Donker PJ: Impotence following radical prostatectomy: Insight into etiology and prevention. J Urol 1982;128: 492–497PubMedGoogle Scholar
  196. Walsh PC, Marschke P, Ricker D, Burnett AL: Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000;55: 58–61PubMedCrossRefGoogle Scholar
  197. Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, Shariat SF, Jeldres C, Graefen M, Bénard F, McCormack M, Valiquette L, Karakiewicz Pl. A nomogram predicting 10 year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007;25: 3576–3581PubMedCrossRefGoogle Scholar
  198. Ward JF, Moul JW: Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining und localizing biochemical recurrence of prostate cancer. Curr Opin Urol 2005;15:181–186PubMedCrossRefGoogle Scholar
  199. Wawroschek F, Vogt H, Wengenmair H, Weckermann D, Hamm M, Keil M, Graf G, Heidenreich P, Harzmann R: Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003;70: 303–310PubMedCrossRefGoogle Scholar
  200. Wei JT, Dunn RL, Marcovich R, Montie JE, Sanda MG: Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol 2000;164: 744–748PubMedCrossRefGoogle Scholar
  201. Wiegel T, Bottke D, Willich N, Piechota H, Siegmann A, Stoeckle M, Ruebe C, Hinke A, Hinkelbein W, Miller K: Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95). ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 5060Google Scholar
  202. Wiegel T, Lohm G, Bottke D, Höcht S, Miller K, Siegmann A, Schostak M, Neumann K, Hinkelbein W: Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome-results of a retrospective study. Int J Radiat Oncol Biol Phys 2008 [Epub ahead of print]Google Scholar
  203. Wirth MP, Hakenberg OW: Brachytherapy for prostate cancer. Urol Int 1999;63;87–91PubMedCrossRefGoogle Scholar
  204. Wirth M, Tyrrell C, Wallace M, Delaere KP, Sanchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes CF, Borchers TM, Morris T, Stone A: Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001;58: 146–51PubMedCrossRefGoogle Scholar
  205. Wirth MP, Herrmann T, Alken P, Kovacs G, Hakenberg OW, Müller H, Ahlemann L, Schalkhäuser K: Empfehlungen zur Durchführung der alleinigen, permanenten, interstitiellen Brachytherapie beim lokal begrenzten Prostatakarzinom. Urologe (A) 2002;41: 369–373CrossRefGoogle Scholar
  206. Wirth MP, Weissbach L, Marx FJ, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M: Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45: 267–270PubMedCrossRefGoogle Scholar
  207. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists’ Group: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004;172: 1865–1870PubMedCrossRefGoogle Scholar
  208. Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J, Wallace DM, Hetherington J, Pina F, Heyns C, Borchers T, Morris T, Armstrong J; ‘Casodex’ Early Prostate Cancer Trialists’ Group: Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis 2005;8: 194–200PubMedCrossRefGoogle Scholar
  209. Wirth MP, Engelhardt FM: PSA-Rezidiv nach primär kurativer Therapie — lokal oder systemisch? Wann ist eine kurative Zweittherapie noch möglich? Urologe A 2005;44:997–1004PubMedCrossRefGoogle Scholar
  210. Wirth MP, Hakenberg OW, Froehner M: Antiandrogens in the treatment of prostate cancer. Eur Urol 2007;51: 306–313PubMedCrossRefGoogle Scholar
  211. Wirth MP, Hakenberg OW, Froehner M: Adjuvant hormonal treatment — the bicalutamide early prostate cancer program. Front Radiat Ther Oncol. 2008;41: 39–48PubMedCrossRefGoogle Scholar
  212. Wolff I, Grimm MO, Wirth M: Lymphadenektomie beim limitierten Lymphknotenrezidiv des Prostatakarzinoms nach kurativer Lokaltherapie. Urologe A 2008;47:1436–1440PubMedCrossRefGoogle Scholar
  213. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294: 1233–1239PubMedCrossRefGoogle Scholar
  214. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM: Long-term-(15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994a;152: 1850–1857PubMedGoogle Scholar
  215. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994b;152: 1850–1857PubMedGoogle Scholar
  216. Zincke H, Lau W, Bergstralh, Blute ML: Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 2001;166: 2208–2215PubMedCrossRefGoogle Scholar
  217. Zwergel U, Lehmann J, Wullich B, Schreier U, Remberger K, Zwergel T, Stoeckle M: Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J Urol 2004; 171: 1128–1131PubMedCrossRefGoogle Scholar

Literatur zu Kap. 25.6

  1. 1.
    Jemal A, Murray T, Ward E et al.: Cancer statistics, 2005. CA Cancer J Clin 2005; 55 (1): 10–30PubMedCrossRefGoogle Scholar
  2. 2.
    Moul JW: Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163 (6): 1632–1642PubMedCrossRefGoogle Scholar
  3. 3.
    Lee WR, Hanks GE, Hanlon A: Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997; 15 (1): 230–238PubMedGoogle Scholar
  4. 4.
    D’Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002; 20 (23): 4567–4573PubMedCrossRefGoogle Scholar
  5. 5.
    Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE: Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 2003; 97 (4): 1127–1133PubMedCrossRefGoogle Scholar
  6. 6.
    Touma NJ, Izawa JI, Chin JL: Current status of local salvage therapies following radiation failure for prostate cancer. J Urol 2005; 173 (2): 373–379PubMedCrossRefGoogle Scholar
  7. 7.
    Grossfeld GD, Li YP, Lubeck DP, Broering JM, Mehta SS, Carroll PR: Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol 2002; 168 (2): 530–535PubMedCrossRefGoogle Scholar
  8. 8.
    Stephenson AJ, Eastham JA: Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005; 23 (32): 8198–8203PubMedCrossRefGoogle Scholar
  9. 9.
    Zelefsky MJ, Leibel SA, Kutcher GJ, Kelson S, Ling CC, Fuks Z: The Feasibility of Dose Escalation with Three-Dimensional Conformal Radiotherapy in Patients with Prostatic Carcinoma. Cancer J Sci Am 1995; 1 (2): 142PubMedGoogle Scholar
  10. 10.
    Zagars GK, Pollack A, von Eschenbach AC: Prostate cancer and radiation therapy—the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995; 33 (1): 23–35PubMedGoogle Scholar
  11. 11.
    Fuks Z, Leibel SA, Wallner KE et al.: The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 1991; 21 (3): 537–547PubMedGoogle Scholar
  12. 12.
    Kaplan ID, Prestidge BR, Bagshaw MA, Cox RS: The importance of local control in the treatment of prostatic cancer. J Urol 1992; 147 (3 Pt 2): 917–921PubMedGoogle Scholar
  13. 13.
    Holzman M, Carlton CE, Jr., Scardino PT: The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer. J Urol 1991; 146 (6): 1578–1582PubMedGoogle Scholar
  14. 14.
    Bianco FJ, Jr., Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Eastham JA: Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62 (2): 448–453PubMedGoogle Scholar
  15. 15.
    Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H: Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer, Vol. 161, 1999 J Urol)Google Scholar
  16. 16.
    Izawa JI, Ajam K, McGuire E et al.: Major surgery to manage definitively severe complications of salvage cryotherapy for prostate cancer. J Urol 2000; 164 (6): 1978–1981PubMedCrossRefGoogle Scholar
  17. 17.
    Rogers E, Ohori M, Kassabian VS, Wheeler TM, Scardino PT: Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995; 153 (1): 104–110PubMedCrossRefGoogle Scholar
  18. 18.
    Gheiler EL, Tefilli MV, Tiguert R et al.: Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 1998; 51 (5): 789–795PubMedCrossRefGoogle Scholar
  19. 19.
    Brenner PC, Russo P, Wood DP, Morse MJ, Donat SM, Fair WR: Salvage radical prostatectomy in the management of locally recurrent prostate cancer after 125I implantation. Br J Urol 1995; 75 (1): 44–47PubMedCrossRefGoogle Scholar
  20. 20.
    Link P, Freiha FS, Stamey TA: Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol 1991; 145 (3): 532–534PubMedGoogle Scholar
  21. 21.
    Moul JW, Paulson DF: The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer 1991; 68 (6): 1265–1271PubMedCrossRefGoogle Scholar
  22. 22.
    Pontes JE, Montie J, Klein E, Huben R: Salvage surgery for radiation failure in prostate cancer. Cancer 1993; 71 (3 Suppl): 976–980PubMedCrossRefGoogle Scholar
  23. 23.
    Stein A, Smith RB, deKernion JB: Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate. Urology 1992; 40 (3): 197–200PubMedCrossRefGoogle Scholar
  24. 24.
    Hanlon AL, Pinover WH, Horwitz EM, Hanks GE: Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 2001; 50 (4): 845–849PubMedCrossRefGoogle Scholar
  25. 25.
    Rosser CJ, Kuban DA, Levy LB et al.: Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 2002; 168 (5): 2001–2005PubMedCrossRefGoogle Scholar
  26. 26.
    Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF: Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999; 17 (4): 1155PubMedGoogle Scholar
  27. 27.
    Kuban DA, Thames HD, Levy LB et al.: Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003; 57 (4): 915–928PubMedGoogle Scholar
  28. 28.
    Shipley WU, Thames HD, Sandler HM et al.: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. Jama 1999; 281 (17): 1598–1604PubMedCrossRefGoogle Scholar
  29. 29.
    Stephenson AJ, Scardino PT, Bianco FJ, Jr., DiBlasio CJ, Fearn PA, Eastham JA: Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004; 172 (6 Pt 1): 2239–2243PubMedCrossRefGoogle Scholar
  30. 30.
    Crook JM, Perry GA, Robertson S, Esche BA: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 1995; 45 (4): 624–31; discussion 631–2PubMedCrossRefGoogle Scholar
  31. 31.
    Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M: Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000; 48 (2): 355–367PubMedGoogle Scholar
  32. 32.
    Scardino PT, Wheeler TM: Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr 1988 (7): 95–103PubMedGoogle Scholar
  33. 33.
    Kabalin JN, Hodge KK, McNeal JE, Freiha FS, Stamey TA: Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 1989; 142 (2 Pt 1): 326–331PubMedGoogle Scholar
  34. 34.
    Borghede G, Aldenborg F, Wurzinger E, Johansson KA, Hedelin H: Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy. Br J Urol 1997; 80 (2): 247–255PubMedGoogle Scholar
  35. 35.
    Zelefsky MJ, Fuks Z, Hunt M et al.: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166 (3): 876–881PubMedCrossRefGoogle Scholar
  36. 36.
    Pollack A, Zagars GK, Starkschall G et al.: Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53 (5): 1097–1105PubMedCrossRefGoogle Scholar
  37. 37.
    Kuban DA, Thames HD, Shipley WU: Defining recurrence after radiation for prostate cancer. J Urol 2005; 173 (6): 1871–1878PubMedCrossRefGoogle Scholar
  38. 38.
    Zietman AL, Tibbs MK, Dallow KC et al.: Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1–2 adenocarcinoma of the prostate. Radiother Oncol 1996; 40 (2): 159–162PubMedCrossRefGoogle Scholar
  39. 39.
    Critz FA, Williams WH, Holladay CT et al.: Post-treatment PSA < or =0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology 1999; 54 (6): 968–71PubMedCrossRefGoogle Scholar
  40. 40.
    Sartor CI, Strawderman MH, Lin XH, Kish KE, McLaughlin PW, Sandler HM: Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 1997; 38 (5): 941–97PubMedGoogle Scholar
  41. 41.
    Sala E, Eberhardt SC, Akin O et al.: Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 2006; 238 (1): 176–183PubMedCrossRefGoogle Scholar
  42. 42.
    Ward JF, Sebo TJ, Blute ML, Zincke H: Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005; 173 (4): 1156–60PubMedCrossRefGoogle Scholar
  43. 43.
    Izawa JI, Madsen LT, Scott SM et al.: Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 2002; 20 (11): 2664–2671PubMedCrossRefGoogle Scholar
  44. 44.
    Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB: Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol 2001; 165 (6 Pt 1): 1937–41; discussion 1941–1942PubMedGoogle Scholar
  45. 45.
    Ghafar MA, Johnson CW, De La Taille A et al.: Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 2001; 166 (4): 1333–7; discussion 1337–1338PubMedCrossRefGoogle Scholar
  46. 46.
    Beyer DC: Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999; 54 (5): 880–883PubMedCrossRefGoogle Scholar
  47. 47.
    Grado GL, Collins JM, Kriegshauser JS et al.: Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999; 53 (1): 2–10PubMedCrossRefGoogle Scholar
  48. 48.
    Garzotto M, Wajsman Z: Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol 1998; 159 (3): 950–4; discussion 954–955PubMedCrossRefGoogle Scholar
  49. 49.
    Ahlering TE, Lieskovsky G, Skinner DG: Salvage surgery plus androgen deprivation for radioresistant prostatic adenocarcinoma. J Urol 1992; 147 (3 Pt 2): 900–902PubMedGoogle Scholar
  50. 50.
    Link P, Freiha FS: Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology 1991; 37 (3): 189–192PubMedCrossRefGoogle Scholar
  51. 51.
    Neerhut GJ, Wheeler T, Cantini M, Scardino PT: Salvage radical prostatectomy for radiorecurrent adenocarcinoma of the prostate. J Urol 1988; 140 (3): 544–9PubMedGoogle Scholar
  52. 52.
    Lerner SE, Blute ML, Zincke H: Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 1995; 154 (3): 1103–1109PubMedCrossRefGoogle Scholar
  53. 53.
    Dillioglugil O, Leibman BD, Leibman NS, Kattan MW, Rosas AL, Scardino PT: Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol 1997; 157 (5): 1760–7PubMedCrossRefGoogle Scholar
  54. 54.
    Perrotte P, Litwin MS, McGuire EJ, Scott SM, von Eschenbach AC, Pisters LL: Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol 1999; 162 (2): 398–402PubMedCrossRefGoogle Scholar
  55. 55.
    Mador DR, Huben RP, Wajsman Z, Pontes JE: Salvage surgery following radical radiotherapy for adenocarcinoma of the prostate. J Urol 1985; 133 (1): 58–60PubMedGoogle Scholar
  56. 56.
    Thompson IM, Rounder JB, Spence CR, Rodriguez FR: Salvage radical prostatectomy for adenocarcinoma of the prostate. Cancer 1988; 61 (7): 1464–1466PubMedCrossRefGoogle Scholar
  57. 57.
    Rainwater LM, Zincke H: Radical prostatectomy after radiation therapy for cancer of the prostate: feasibility and prognosis. J Urol 1988; 140 (6): 1455–1459PubMedGoogle Scholar
  58. 58.
    Zincke H: Radical prostatectomy and exenterative procedures for local failure after radiotherapy with curative intent: comparison of outcomes. J Urol 1992; 147 (3 Pt 2): 894–899PubMedGoogle Scholar
  59. 59.
    Vaidya A, Soloway MS: Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited. J Urol 2000; 164 (6): 1998–2001PubMedCrossRefGoogle Scholar
  60. 60.
    Vallancien G, Gupta R, Cathelineau X, Baumert H, Rozet F: Initial results of salvage laparoscopic radical prostatectomy after radiation failure. J Urol 2003; 170 (5): 1838–1840PubMedCrossRefGoogle Scholar
  61. 61.
    Han KR, Cohen JK, Miller RJ et al.: Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 2003; 170 (4 Pt 1): 1126–30PubMedCrossRefGoogle Scholar
  62. 62.
    Miller RJ, Jr., Cohen JK, Shuman B, Merlotti LA: Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma. Cancer 1996; 77 (8): 1510–1514PubMedCrossRefGoogle Scholar
  63. 63.
    Bales GT, Williams MJ, Sinner M, Thisted RA, Chodak GW: Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology 1995; 46 (5): 676–680PubMedCrossRefGoogle Scholar
  64. 64.
    Pisters LL, Perrotte P, Scott SM, Greene GF, von Eschenbach AC Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy. J Clin Oncol 1999; 17 (8): 2514–2520PubMedGoogle Scholar
  65. 65.
    Long JP, Fallick ML, LaRock DR, Rand W: Preliminary outcomes following cryosurgical ablation of the prostate in patients with clinically localized prostate carcinoma. J Urol 1998; 159 (2): 477–484